WO2012087519A1 - Compositions and methods for modulating fxr - Google Patents
Compositions and methods for modulating fxr Download PDFInfo
- Publication number
- WO2012087519A1 WO2012087519A1 PCT/US2011/062724 US2011062724W WO2012087519A1 WO 2012087519 A1 WO2012087519 A1 WO 2012087519A1 US 2011062724 W US2011062724 W US 2011062724W WO 2012087519 A1 WO2012087519 A1 WO 2012087519A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methoxy
- cyclopropyl
- octan
- azabicyclo
- oxazol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 87
- 239000000203 mixture Substances 0.000 title description 91
- 150000001875 compounds Chemical class 0.000 claims abstract description 246
- 150000003839 salts Chemical class 0.000 claims abstract description 74
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 41
- 150000001413 amino acids Chemical class 0.000 claims abstract description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 475
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 387
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 263
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 186
- ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 claims description 160
- -1 bicyclo[3.1.0]hexanyl Chemical group 0.000 claims description 137
- 235000001968 nicotinic acid Nutrition 0.000 claims description 96
- 239000011664 nicotinic acid Substances 0.000 claims description 96
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 93
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 239000003814 drug Substances 0.000 claims description 61
- 125000000217 alkyl group Chemical group 0.000 claims description 57
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 52
- PVNIIMVLHYAWGP-UHFFFAOYSA-M nicotinate Chemical compound [O-]C(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-M 0.000 claims description 44
- 238000011282 treatment Methods 0.000 claims description 41
- 201000010099 disease Diseases 0.000 claims description 37
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 36
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 34
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 32
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 claims description 32
- 206010008635 Cholestasis Diseases 0.000 claims description 31
- 239000002253 acid Substances 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 29
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 27
- 230000001404 mediated effect Effects 0.000 claims description 26
- 230000007870 cholestasis Effects 0.000 claims description 25
- 231100000359 cholestasis Toxicity 0.000 claims description 25
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 25
- 125000003003 spiro group Chemical group 0.000 claims description 25
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 24
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 claims description 24
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 23
- NIPZZXUFJPQHNH-UHFFFAOYSA-N pyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-N 0.000 claims description 22
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 21
- YPOXGDJGKBXRFP-UHFFFAOYSA-M pyrimidine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-M 0.000 claims description 21
- 229940124597 therapeutic agent Drugs 0.000 claims description 21
- NIPZZXUFJPQHNH-UHFFFAOYSA-M pyrazine-2-carboxylate Chemical compound [O-]C(=O)C1=CN=CC=N1 NIPZZXUFJPQHNH-UHFFFAOYSA-M 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 17
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 17
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 17
- 201000001883 cholelithiasis Diseases 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 15
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- IIVUJUOJERNGQX-UHFFFAOYSA-N pyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=CN=C1 IIVUJUOJERNGQX-UHFFFAOYSA-N 0.000 claims description 14
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 13
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 13
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- 206010016654 Fibrosis Diseases 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 9
- 208000001130 gallstones Diseases 0.000 claims description 9
- 230000000968 intestinal effect Effects 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 230000000750 progressive effect Effects 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 8
- 210000000013 bile duct Anatomy 0.000 claims description 8
- 230000007882 cirrhosis Effects 0.000 claims description 8
- 229940011871 estrogen Drugs 0.000 claims description 8
- 239000000262 estrogen Substances 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- RUUOPSRRIKJHNH-UHFFFAOYSA-N pyridazine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=N1 RUUOPSRRIKJHNH-UHFFFAOYSA-N 0.000 claims description 8
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 8
- ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- DJXNJVFEFSWHLY-UHFFFAOYSA-N quinoline-3-carboxylic acid Chemical compound C1=CC=CC2=CC(C(=O)O)=CN=C21 DJXNJVFEFSWHLY-UHFFFAOYSA-N 0.000 claims description 8
- VXGYRCVTBHVXMZ-UHFFFAOYSA-N quinoline-6-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CC=C21 VXGYRCVTBHVXMZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 7
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 7
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 7
- OFFSPAZVIVZPHU-UHFFFAOYSA-N Benzofurane-2-carboxylic acid Natural products C1=CC=C2OC(C(=O)O)=CC2=C1 OFFSPAZVIVZPHU-UHFFFAOYSA-N 0.000 claims description 6
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- 208000012868 Overgrowth Diseases 0.000 claims description 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 6
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Natural products OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- 206010056375 Bile duct obstruction Diseases 0.000 claims description 5
- 208000021130 Bilirubin encephalopathy Diseases 0.000 claims description 5
- 206010049055 Cholestasis of pregnancy Diseases 0.000 claims description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 5
- 206010023126 Jaundice Diseases 0.000 claims description 5
- 208000012347 Parenteral nutrition associated liver disease Diseases 0.000 claims description 5
- 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 125000001246 bromo group Chemical group Br* 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 206010009887 colitis Diseases 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 201000001881 impotence Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000006663 kernicterus Diseases 0.000 claims description 5
- 208000007232 portal hypertension Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- PAHUYNCPPWKLKS-UHFFFAOYSA-N ethyl 2-[3-[(5-cyclopropyl-3-spiro[2.5]octan-6-yl-1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OCC)=CC=C2N=C1N1C(C2)CCC1CC2OCC=1C(C2CCC3(CC3)CC2)=NOC=1C1CC1 PAHUYNCPPWKLKS-UHFFFAOYSA-N 0.000 claims description 4
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- SRKXVESHUPPYMO-UHFFFAOYSA-N quinazoline-7-carboxylic acid Chemical compound C1=NC=NC2=CC(C(=O)O)=CC=C21 SRKXVESHUPPYMO-UHFFFAOYSA-N 0.000 claims description 4
- RAYMXZBXQCGRGX-UHFFFAOYSA-N quinoline-5-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=N1 RAYMXZBXQCGRGX-UHFFFAOYSA-N 0.000 claims description 4
- 125000003031 C5-C7 cycloalkylene group Chemical group 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- VRHVXPIGPYQXTK-UHFFFAOYSA-N ethyl 2-[3-[[5-cyclopropyl-3-(2-phenylcyclopropyl)-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OCC)=CC=C2N=C1N1C(C2)CCC1CC2OCC=1C(C2C(C2)C=2C=CC=CC=2)=NOC=1C1CC1 VRHVXPIGPYQXTK-UHFFFAOYSA-N 0.000 claims description 3
- PSFXMIXXCHQRIZ-UHFFFAOYSA-N methyl 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OC)=CC(OC)=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F PSFXMIXXCHQRIZ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 3
- QKJRWFAYJANPFP-JWTNVVGKSA-N 2-[(1S,5R)-3-[[5-cyclopropyl-3-[2-(difluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]pyrimidine-5-carboxylic acid Chemical compound C([C@]1(CC[C@@](C2)(N1C=1N=CC(=CN=1)C(O)=O)[H])[H])C2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)F QKJRWFAYJANPFP-JWTNVVGKSA-N 0.000 claims description 2
- DWUROSGFRATIBA-UHFFFAOYSA-N 2-[3-[(3-cyclohexyl-5-cyclopropyl-1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-6-methylpyrimidine-4-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NC(N2C3CCC2CC(C3)OCC2=C(ON=C2C2CCCCC2)C2CC2)=N1 DWUROSGFRATIBA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001847 2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- RYVDUSQJUULCPP-JWTNVVGKSA-N 4-[(1S,5R)-3-[[5-cyclopropyl-3-[2-(difluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-3,5-difluorobenzoic acid Chemical compound C([C@]1(CC[C@@](C2)(N1C=1C(=CC(=CC=1F)C(O)=O)F)[H])[H])C2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)F RYVDUSQJUULCPP-JWTNVVGKSA-N 0.000 claims description 2
- QGIMFXFZCOOZGR-UHFFFAOYSA-N 4-[3-[[5-cyclopropyl-3-[2-(difluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-3-fluorobenzonitrile Chemical compound FC(F)OC1=CC=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2C=3C(=CC(=CC=3)C#N)F)CCC2C1 QGIMFXFZCOOZGR-UHFFFAOYSA-N 0.000 claims description 2
- ZYBROCDFEMYQFT-SJPCQFCGSA-N 5-[(1S,5R)-3-[[5-cyclopropyl-3-[2-(difluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]pyrazine-2-carboxylic acid Chemical compound C([C@]1(CC[C@@](C2)(N1C=1N=CC(=NC=1)C(O)=O)[H])[H])C2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)F ZYBROCDFEMYQFT-SJPCQFCGSA-N 0.000 claims description 2
- XYRSHGRFBQTMCX-UHFFFAOYSA-N 5-[3-[[3-(2-chlorophenyl)-5-cyclopropyl-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-methyl-1-benzofuran-2-carboxylic acid Chemical compound C1=CC=2OC(C(O)=O)=CC=2C(C)=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1Cl XYRSHGRFBQTMCX-UHFFFAOYSA-N 0.000 claims description 2
- KIJXCALLIPCIQT-UHFFFAOYSA-N 6-[2-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carbonyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(O)C(O)C(O)C1OC(=O)C1=CC(F)=C(N=C(S2)N3C4CCC3CC(C4)OCC=3C(=NOC=3C3CC3)C=3C(=CC=CC=3)OC(F)(F)F)C2=C1 KIJXCALLIPCIQT-UHFFFAOYSA-N 0.000 claims description 2
- CYGZQZZTIFBPQG-UHFFFAOYSA-N 6-[2-[3-[[5-cyclopropyl-3-[2-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carbonyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(O)C(O)C(O)C1OC(=O)C1=CC(F)=C(N=C(S2)N3C4CCC3CC(C4)OCC=3C(=NOC=3C3CC3)C=3C(=CC=CC=3)C(F)(F)F)C2=C1 CYGZQZZTIFBPQG-UHFFFAOYSA-N 0.000 claims description 2
- NCLHJGPROHOKSV-UHFFFAOYSA-N 6-[6-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]pyridine-3-carbonyl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(O)C(O)C(O)C1OC(=O)C1=CC=C(N2C3CCC2CC(C3)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)OC(F)(F)F)N=C1 NCLHJGPROHOKSV-UHFFFAOYSA-N 0.000 claims description 2
- UMFLZDQQKWZSJO-CMTVVOJYSA-N ethyl 2-[3-[[5-cyclopropyl-3-[(1r,2r)-2-(trifluoromethyl)cyclohexyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OCC)=CC=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1[C@@H]1CCCC[C@H]1C(F)(F)F UMFLZDQQKWZSJO-CMTVVOJYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- VULMVCYAGYDIFW-UHFFFAOYSA-N methyl 2-[3-[(3-cyclohexyl-5-cyclopropyl-1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-6-methylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC(C)=NC(N2C3CCC2CC(C3)OCC2=C(ON=C2C2CCCCC2)C2CC2)=N1 VULMVCYAGYDIFW-UHFFFAOYSA-N 0.000 claims description 2
- NQOOGMPONTYEEM-UHFFFAOYSA-N methyl 2-[3-[(5-cyclopropyl-3-spiro[2.5]octan-6-yl-1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OC)=CC(F)=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C(CC1)CCC21CC2 NQOOGMPONTYEEM-UHFFFAOYSA-N 0.000 claims description 2
- QTAOZFGZKCQQPH-UHFFFAOYSA-N methyl 2-[3-[(5-cyclopropyl-3-spiro[2.5]octan-6-yl-1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OC)=CC(OC)=C2N=C1N1C(C2)CCC1CC2OCC=1C(C2CCC3(CC3)CC2)=NOC=1C1CC1 QTAOZFGZKCQQPH-UHFFFAOYSA-N 0.000 claims description 2
- QCIUYFIACKJUMS-NCYZIPQMSA-N methyl 2-[3-[[5-cyclopropyl-3-[(1S,2S)-2-(trifluoromethyl)cyclohexyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-methylpyrimidine-5-carboxylate Chemical compound N1=C(C)C(C(=O)OC)=CN=C1N1C2CCC1CC(OCC1=C(ON=C1[C@@H]1[C@H](CCCC1)C(F)(F)F)C1CC1)C2 QCIUYFIACKJUMS-NCYZIPQMSA-N 0.000 claims description 2
- QCIUYFIACKJUMS-UHFFFAOYSA-N methyl 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethyl)cyclohexyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-methylpyrimidine-5-carboxylate Chemical compound N1=C(C)C(C(=O)OC)=CN=C1N1C2CCC1CC(OCC1=C(ON=C1C1C(CCCC1)C(F)(F)F)C1CC1)C2 QCIUYFIACKJUMS-UHFFFAOYSA-N 0.000 claims description 2
- OKHFCMXFULXXPE-UHFFFAOYSA-N methyl 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OC)=CC(OC)=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1C(F)(F)F OKHFCMXFULXXPE-UHFFFAOYSA-N 0.000 claims description 2
- XGWAAZNWQNSRMS-UHFFFAOYSA-N methyl 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-6-methylpyrimidine-4-carboxylate Chemical compound COC(=O)C1=CC(C)=NC(N2C3CCC2CC(C3)OCC=2C(=NOC=2C2CC2)C=2C(=CC=CC=2)C(F)(F)F)=N1 XGWAAZNWQNSRMS-UHFFFAOYSA-N 0.000 claims description 2
- RUHPZGQSJRAYNF-UHFFFAOYSA-N methyl 4-chloro-6-[3-[[5-cyclopropyl-3-[2-(difluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]pyridine-3-carboxylate Chemical compound C1=C(Cl)C(C(=O)OC)=CN=C1N1C2CCC1CC(OCC=1C(=NOC=1C1CC1)C=1C(=CC=CC=1)OC(F)F)C2 RUHPZGQSJRAYNF-UHFFFAOYSA-N 0.000 claims description 2
- RHKUGCBIKHMIKS-HHVWMZHCSA-N methyl 5-[3-[[5-cyclopropyl-3-[(1s,2s)-2-(trifluoromethyl)cyclohexyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]pyrazine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CN=C1N1C2CCC1CC(OCC1=C(ON=C1[C@@H]1[C@H](CCCC1)C(F)(F)F)C1CC1)C2 RHKUGCBIKHMIKS-HHVWMZHCSA-N 0.000 claims description 2
- RHKUGCBIKHMIKS-UHFFFAOYSA-N methyl 5-[3-[[5-cyclopropyl-3-[2-(trifluoromethyl)cyclohexyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]pyrazine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CN=C1N1C2CCC1CC(OCC1=C(ON=C1C1C(CCCC1)C(F)(F)F)C1CC1)C2 RHKUGCBIKHMIKS-UHFFFAOYSA-N 0.000 claims description 2
- CNFKPBGTYDCSGK-UHFFFAOYSA-N methyl 5-bromo-6-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]pyridine-3-carboxylate Chemical compound BrC1=CC(C(=O)OC)=CN=C1N1C2CCC1CC(OCC=1C(=NOC=1C1CC1)C=1C(=CC=CC=1)OC(F)(F)F)C2 CNFKPBGTYDCSGK-UHFFFAOYSA-N 0.000 claims description 2
- YROTXHFHKXBTKS-UHFFFAOYSA-N methyl 5-cyclopropyl-6-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]pyridine-3-carboxylate Chemical compound C1CC1C1=CC(C(=O)OC)=CN=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F YROTXHFHKXBTKS-UHFFFAOYSA-N 0.000 claims description 2
- GDCPZAJATUEWQQ-UHFFFAOYSA-N methyl 6-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-1,2-benzothiazole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=NSC2=CC=1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F GDCPZAJATUEWQQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000005550 pyrazinylene group Chemical group 0.000 claims description 2
- 125000005551 pyridylene group Chemical group 0.000 claims description 2
- 125000005576 pyrimidinylene group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000005557 thiazolylene group Chemical group 0.000 claims description 2
- TWBYWOBDOCUKOW-ZQBYOMGUSA-N pyridine-4-carboxylic acid Chemical compound O[14C](=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-ZQBYOMGUSA-N 0.000 claims 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 1
- 229940126142 compound 16 Drugs 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 217
- 239000000243 solution Substances 0.000 description 165
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 161
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 156
- 238000006243 chemical reaction Methods 0.000 description 110
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 88
- 235000019439 ethyl acetate Nutrition 0.000 description 84
- 102100038495 Bile acid receptor Human genes 0.000 description 78
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 72
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 71
- 239000007787 solid Substances 0.000 description 61
- 239000000543 intermediate Substances 0.000 description 57
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 54
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 52
- 238000005160 1H NMR spectroscopy Methods 0.000 description 50
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 40
- 239000011541 reaction mixture Substances 0.000 description 36
- 239000000047 product Substances 0.000 description 35
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 34
- 239000012267 brine Substances 0.000 description 33
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 33
- 239000002904 solvent Substances 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 32
- 238000003756 stirring Methods 0.000 description 32
- 239000003921 oil Substances 0.000 description 30
- 235000019198 oils Nutrition 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 28
- 239000000725 suspension Substances 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 26
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 25
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 22
- 239000000651 prodrug Substances 0.000 description 22
- 229940002612 prodrug Drugs 0.000 description 22
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- 238000004587 chromatography analysis Methods 0.000 description 19
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 19
- 229940024606 amino acid Drugs 0.000 description 17
- 229910052805 deuterium Inorganic materials 0.000 description 17
- 239000012074 organic phase Substances 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- 239000012280 lithium aluminium hydride Substances 0.000 description 15
- 229910052757 nitrogen Inorganic materials 0.000 description 15
- 238000000746 purification Methods 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000007864 aqueous solution Substances 0.000 description 12
- 239000003613 bile acid Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 239000004480 active ingredient Substances 0.000 description 11
- 239000002585 base Substances 0.000 description 11
- 239000013078 crystal Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- 239000000377 silicon dioxide Substances 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000001412 amines Chemical class 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 9
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 9
- RIJWDPRXCXJDPK-UHFFFAOYSA-N methyl 3-cyclopropyl-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1CC1 RIJWDPRXCXJDPK-UHFFFAOYSA-N 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 7
- 229910010084 LiAlH4 Inorganic materials 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 238000005481 NMR spectroscopy Methods 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 101150027485 NR1H4 gene Proteins 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 210000000941 bile Anatomy 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 230000001587 cholestatic effect Effects 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- UZEWNQNXRAJOFF-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound FC(F)(F)OC1=CC=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 UZEWNQNXRAJOFF-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 235000015165 citric acid Nutrition 0.000 description 5
- 239000013058 crude material Substances 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 229940113088 dimethylacetamide Drugs 0.000 description 5
- DWXKSCKBUSAOKS-UHFFFAOYSA-N ethyl 2-chloro-3-oxopropanoate Chemical compound CCOC(=O)C(Cl)C=O DWXKSCKBUSAOKS-UHFFFAOYSA-N 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 5
- 239000003039 volatile agent Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 4
- MDOJMKSZNORAKR-UHFFFAOYSA-N 4-iodo-5-methylpyridin-2-amine Chemical compound CC1=CN=C(N)C=C1I MDOJMKSZNORAKR-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 230000003510 anti-fibrotic effect Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- UXOLDCOJRAMLTQ-UTCJRWHESA-N ethyl (2z)-2-chloro-2-hydroxyiminoacetate Chemical compound CCOC(=O)C(\Cl)=N\O UXOLDCOJRAMLTQ-UTCJRWHESA-N 0.000 description 4
- LQMQUNDZYMYZSA-UHFFFAOYSA-N ethyl 6-chloro-1-methylindazole-3-carboxylate Chemical compound ClC1=CC=C2C(C(=O)OCC)=NN(C)C2=C1 LQMQUNDZYMYZSA-UHFFFAOYSA-N 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- SGWVZBCLQAXEJM-UHFFFAOYSA-N methyl 2-bromo-4-fluoro-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(F)=C2N=C(Br)SC2=C1 SGWVZBCLQAXEJM-UHFFFAOYSA-N 0.000 description 4
- DVAQLKVNVWANSR-UHFFFAOYSA-N methyl 2-chloro-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(Cl)SC2=C1 DVAQLKVNVWANSR-UHFFFAOYSA-N 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- SEGZJJSZYOEABC-UHFFFAOYSA-N tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(O)CC2CCC1N2C(=O)OC(C)(C)C SEGZJJSZYOEABC-UHFFFAOYSA-N 0.000 description 4
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 3
- FHXCPNRGTWFGQQ-UHFFFAOYSA-N 4-(chloromethyl)-5-cyclopropyl-3-(2-phenylcyclopropyl)-1,2-oxazole Chemical compound ClCC=1C(C2C(C2)C=2C=CC=CC=2)=NOC=1C1CC1 FHXCPNRGTWFGQQ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- BYTNEISLBIENSA-MDZDMXLPSA-N GW 4064 Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(C=C1Cl)=CC=C1\C=C\C1=CC=CC(C(O)=O)=C1 BYTNEISLBIENSA-MDZDMXLPSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- BQDXBKVSCIWSIJ-UHFFFAOYSA-N [2-(trifluoromethyl)pyridin-3-yl]methanol Chemical compound OCC1=CC=CN=C1C(F)(F)F BQDXBKVSCIWSIJ-UHFFFAOYSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 239000000460 chlorine Chemical group 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- XISSCVMIXDMKLH-UHFFFAOYSA-N ethyl 2-chloro-1,3-benzothiazole-6-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=C(Cl)SC2=C1 XISSCVMIXDMKLH-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002443 hepatoprotective effect Effects 0.000 description 3
- 150000002431 hydrogen Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- FKMZNQQOPCCUTD-UHFFFAOYSA-N methyl 3-fluoro-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 FKMZNQQOPCCUTD-UHFFFAOYSA-N 0.000 description 3
- DOMJYWCXCVFKCA-UHFFFAOYSA-N methyl 4-amino-3-fluorobenzoate Chemical compound COC(=O)C1=CC=C(N)C(F)=C1 DOMJYWCXCVFKCA-UHFFFAOYSA-N 0.000 description 3
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 3
- 230000001483 mobilizing effect Effects 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N n-propyl alcohol Natural products CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229960005235 piperonyl butoxide Drugs 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003797 solvolysis reaction Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- DYWNLSQWJMTVGJ-UHFFFAOYSA-N (1-hydroxy-1-phenylpropan-2-yl)azanium;chloride Chemical compound Cl.CC(N)C(O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-UHFFFAOYSA-N 0.000 description 2
- LCZKSSFWTSEFBD-NTUHNPAUSA-N (1e)-n-hydroxy-2-(trifluoromethoxy)benzenecarboximidoyl chloride Chemical compound O\N=C(\Cl)C1=CC=CC=C1OC(F)(F)F LCZKSSFWTSEFBD-NTUHNPAUSA-N 0.000 description 2
- QCTJVDNQJPCXPB-UHFFFAOYSA-N (2-methylidenecyclohexyl)methoxymethylbenzene Chemical compound C=C1CCCCC1COCC1=CC=CC=C1 QCTJVDNQJPCXPB-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- ARLLNMVPNCXCIM-TWGQIWQCSA-N (nz)-n-[(2-methylphenyl)methylidene]hydroxylamine Chemical compound CC1=CC=CC=C1\C=N/O ARLLNMVPNCXCIM-TWGQIWQCSA-N 0.000 description 2
- ZMULZVILNURIQY-XGICHPGQSA-N (nz)-n-[[2-(trifluoromethoxy)phenyl]methylidene]hydroxylamine Chemical compound O\N=C/C1=CC=CC=C1OC(F)(F)F ZMULZVILNURIQY-XGICHPGQSA-N 0.000 description 2
- LYPXTDXYEQEIIN-UHFFFAOYSA-N 1,2-oxazole-4-carboxylic acid Chemical compound OC(=O)C=1C=NOC=1 LYPXTDXYEQEIIN-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- COMFXXABDQGVSV-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine-3-carbaldehyde Chemical compound FC(F)(F)C1=NC=CC=C1C=O COMFXXABDQGVSV-UHFFFAOYSA-N 0.000 description 2
- NSVXPDGPDFEOHH-UHFFFAOYSA-N 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-1,3-benzothiazole-6-carboxylic acid Chemical compound S1C2=CC(C(=O)O)=CC=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F NSVXPDGPDFEOHH-UHFFFAOYSA-N 0.000 description 2
- VYLOOGHLKSNNEK-UHFFFAOYSA-N 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid Chemical compound S1C2=CC(C(=O)O)=CC(F)=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F VYLOOGHLKSNNEK-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- OLBIQOCEJHLJAG-UHFFFAOYSA-N 3-(4-bicyclo[4.1.0]heptanyl)-5-cyclopropyl-1,2-oxazole-4-carboxylic acid Chemical compound O1N=C(C2CC3CC3CC2)C(C(=O)O)=C1C1CC1 OLBIQOCEJHLJAG-UHFFFAOYSA-N 0.000 description 2
- AAEIBLQPASHLSV-UHFFFAOYSA-N 4,4-dimethylcyclohexane-1-carbaldehyde Chemical compound CC1(C)CCC(C=O)CC1 AAEIBLQPASHLSV-UHFFFAOYSA-N 0.000 description 2
- KNJZTGCBZNJVJH-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(2-cyclopropylphenyl)-1,2-oxazole Chemical compound C1C(N2)CCC2CC1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1C1CC1 KNJZTGCBZNJVJH-UHFFFAOYSA-N 0.000 description 2
- VFVLDFUTPZDQKW-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-[2-(difluoromethoxy)phenyl]-1,2-oxazole Chemical compound FC(F)OC1=CC=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 VFVLDFUTPZDQKW-UHFFFAOYSA-N 0.000 description 2
- CFBXDBPJGIKCBP-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-[2-(trifluoromethyl)phenyl]-1,2-oxazole Chemical compound FC(F)(F)C1=CC=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 CFBXDBPJGIKCBP-UHFFFAOYSA-N 0.000 description 2
- IOWMWCDKYVFADS-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-[2-(trifluoromethyl)pyridin-3-yl]-1,2-oxazole Chemical compound FC(F)(F)C1=NC=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 IOWMWCDKYVFADS-UHFFFAOYSA-N 0.000 description 2
- YRAYDVBECHQSKB-UHFFFAOYSA-N 4-(bromomethyl)-5-cyclopropyl-3-(2-methylphenyl)-1,2-oxazole Chemical compound CC1=CC=CC=C1C1=NOC(C2CC2)=C1CBr YRAYDVBECHQSKB-UHFFFAOYSA-N 0.000 description 2
- FXKNMAXKCXZYMC-UHFFFAOYSA-N 4-(chloromethyl)-5-cyclopropyl-3-(4,4-dimethylcyclohexyl)-1,2-oxazole Chemical compound C1CC(C)(C)CCC1C1=NOC(C2CC2)=C1CCl FXKNMAXKCXZYMC-UHFFFAOYSA-N 0.000 description 2
- JFFLVSATSXOJMP-UHFFFAOYSA-N 4-(chloromethyl)-5-cyclopropyl-3-spiro[2.5]octan-8-yl-1,2-oxazole Chemical compound ClCC1=C(C2CC2)ON=C1C1CCCCC11CC1 JFFLVSATSXOJMP-UHFFFAOYSA-N 0.000 description 2
- WDIMSTAJCXSSAT-UHFFFAOYSA-N 4-(methoxymethylidene)-1,1-dimethylcyclohexane Chemical compound COC=C1CCC(C)(C)CC1 WDIMSTAJCXSSAT-UHFFFAOYSA-N 0.000 description 2
- BVPIKJOUCKPVHU-UHFFFAOYSA-N 4-bicyclo[4.1.0]heptanylmethanol Chemical compound C1C(CO)CCC2CC21 BVPIKJOUCKPVHU-UHFFFAOYSA-N 0.000 description 2
- HJFGELBIFHDUIS-UHFFFAOYSA-N 4-bromo-5-fluoro-1,2-benzothiazole-3-carboxamide Chemical compound C1=C(F)C(Br)=C2C(C(=O)N)=NSC2=C1 HJFGELBIFHDUIS-UHFFFAOYSA-N 0.000 description 2
- ZRSZFHIOMYCYMM-UHFFFAOYSA-N 5-cyclopropyl-3-(2-phenylcyclopropyl)-1,2-oxazole-4-carboxylic acid Chemical compound OC(=O)C=1C(C2C(C2)C=2C=CC=CC=2)=NOC=1C1CC1 ZRSZFHIOMYCYMM-UHFFFAOYSA-N 0.000 description 2
- DHURTFIHYXHSJL-UHFFFAOYSA-N 5-cyclopropyl-3-spiro[2.5]octan-8-yl-1,2-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=C(C2CC2)ON=C1C1CCCCC11CC1 DHURTFIHYXHSJL-UHFFFAOYSA-N 0.000 description 2
- QORFZFGLQOMAJK-UHFFFAOYSA-N 6-bromo-5-fluoro-1,2-benzothiazole-3-carboxamide Chemical compound BrC1=C(F)C=C2C(C(=O)N)=NSC2=C1 QORFZFGLQOMAJK-UHFFFAOYSA-N 0.000 description 2
- OPSZNKWFQHPJIP-UHFFFAOYSA-N 6-bromo-5-fluoro-1,2-benzothiazole-3-carboxylic acid Chemical compound BrC1=C(F)C=C2C(C(=O)O)=NSC2=C1 OPSZNKWFQHPJIP-UHFFFAOYSA-N 0.000 description 2
- MGNQBFCYSJMUQW-UHFFFAOYSA-N 6-bromo-5-fluoro-1-benzothiophene-2,3-dione Chemical compound C1=C(Br)C(F)=CC2=C1SC(=O)C2=O MGNQBFCYSJMUQW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 102100028282 Bile salt export pump Human genes 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 102000034527 Retinoid X Receptors Human genes 0.000 description 2
- 108010038912 Retinoid X Receptors Proteins 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- UGQKLLSYEZFSHO-UHFFFAOYSA-N [5-cyclopropyl-3-(2-methylphenyl)-1,2-oxazol-4-yl]methanol Chemical compound CC1=CC=CC=C1C1=NOC(C2CC2)=C1CO UGQKLLSYEZFSHO-UHFFFAOYSA-N 0.000 description 2
- YJPRZVHHSVCUIU-UHFFFAOYSA-N [5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F YJPRZVHHSVCUIU-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002202 anti-cholestatic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- POCVPBVIDMXXGU-UHFFFAOYSA-N bicyclo[4.1.0]heptane-4-carbaldehyde Chemical compound C1C(C=O)CCC2CC21 POCVPBVIDMXXGU-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 2
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- HCAHLQHNWPLAPH-UHFFFAOYSA-N ethyl 6-chloro-1-(oxan-2-yl)indazole-3-carboxylate Chemical compound C12=CC(Cl)=CC=C2C(C(=O)OCC)=NN1C1CCCCO1 HCAHLQHNWPLAPH-UHFFFAOYSA-N 0.000 description 2
- UBJMOSKYDGJVLU-UHFFFAOYSA-N ethyl spiro[2.5]octane-6-carboxylate Chemical compound C1CC(C(=O)OCC)CCC11CC1 UBJMOSKYDGJVLU-UHFFFAOYSA-N 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- OAEFZZKZXMEPMZ-UHFFFAOYSA-N methyl 1-oxidoquinolin-1-ium-5-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC=CC2=[N+]1[O-] OAEFZZKZXMEPMZ-UHFFFAOYSA-N 0.000 description 2
- IGPCMYNLOWGHAT-UHFFFAOYSA-N methyl 2,4-dibromo-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(Br)=C2N=C(Br)SC2=C1 IGPCMYNLOWGHAT-UHFFFAOYSA-N 0.000 description 2
- DKBKOPMSQPEFGN-UHFFFAOYSA-N methyl 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OC)=CC(F)=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F DKBKOPMSQPEFGN-UHFFFAOYSA-N 0.000 description 2
- IKKRGORQBKUVHQ-UHFFFAOYSA-N methyl 2-amino-4-bromo-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(Br)=C2N=C(N)SC2=C1 IKKRGORQBKUVHQ-UHFFFAOYSA-N 0.000 description 2
- UNJLICBWHHMOFV-UHFFFAOYSA-N methyl 2-amino-4-fluoro-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(F)=C2N=C(N)SC2=C1 UNJLICBWHHMOFV-UHFFFAOYSA-N 0.000 description 2
- SYZNSAWWLCRFFT-UHFFFAOYSA-N methyl 2-amino-4-methoxy-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2N=C(N)SC2=C1 SYZNSAWWLCRFFT-UHFFFAOYSA-N 0.000 description 2
- UCCRMZWBOIVMKI-UHFFFAOYSA-N methyl 2-amino-4-methyl-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(C)=C2N=C(N)SC2=C1 UCCRMZWBOIVMKI-UHFFFAOYSA-N 0.000 description 2
- INMVEWNAYCVPAI-UHFFFAOYSA-N methyl 5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole-4-carboxylate Chemical compound COC(=O)C1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F INMVEWNAYCVPAI-UHFFFAOYSA-N 0.000 description 2
- LLWCAHFEDSDTQN-UHFFFAOYSA-N methyl 6-fluoro-2-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(F)N=C1C LLWCAHFEDSDTQN-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 102000004233 multidrug resistance protein 3 Human genes 0.000 description 2
- 108090000743 multidrug resistance protein 3 Proteins 0.000 description 2
- KGVPSHGTMGATJP-UHFFFAOYSA-N n-(4-bicyclo[4.1.0]heptanylmethylidene)hydroxylamine Chemical compound C1C(C=NO)CCC2CC21 KGVPSHGTMGATJP-UHFFFAOYSA-N 0.000 description 2
- HJZCXYUHNJLWOR-UHFFFAOYSA-N n-(spiro[2.5]octan-8-ylmethylidene)hydroxylamine Chemical compound ON=CC1CCCCC11CC1 HJZCXYUHNJLWOR-UHFFFAOYSA-N 0.000 description 2
- DUKRBPQZSCQFCK-UHFFFAOYSA-N n-[(4,4-dimethylcyclohexyl)methylidene]hydroxylamine Chemical compound CC1(C)CCC(C=NO)CC1 DUKRBPQZSCQFCK-UHFFFAOYSA-N 0.000 description 2
- KDTIJJKGXRNGSM-UHFFFAOYSA-N n-hydroxy-4,4-dimethylcyclohexane-1-carboximidoyl chloride Chemical compound CC1(C)CCC(C(Cl)=NO)CC1 KDTIJJKGXRNGSM-UHFFFAOYSA-N 0.000 description 2
- URESRTNLHMSSFV-UHFFFAOYSA-N n-hydroxybicyclo[4.1.0]heptane-4-carboximidoyl chloride Chemical compound C1C(C(Cl)=NO)CCC2CC21 URESRTNLHMSSFV-UHFFFAOYSA-N 0.000 description 2
- BGWCADAJWREJDS-UHFFFAOYSA-N n-hydroxyspiro[2.5]octane-8-carboximidoyl chloride Chemical compound ON=C(Cl)C1CCCCC11CC1 BGWCADAJWREJDS-UHFFFAOYSA-N 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002206 pro-fibrotic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- STWNGMSGPBZFMX-UHFFFAOYSA-N pyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1.NC(=O)C1=CC=CN=C1 STWNGMSGPBZFMX-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- CPOBXDZHERXVFP-UHFFFAOYSA-N spiro[2.5]octan-6-ylmethanol Chemical compound C1CC(CO)CCC11CC1 CPOBXDZHERXVFP-UHFFFAOYSA-N 0.000 description 2
- GZDLXLFRSFJCPQ-UHFFFAOYSA-N spiro[2.5]octane-8-carbaldehyde Chemical compound O=CC1CCCCC11CC1 GZDLXLFRSFJCPQ-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- AOSKTTCCMBUQAB-UHFFFAOYSA-N tert-butyl 3-[(3-cyclohexyl-5-cyclopropyl-1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2OCC=1C(C2CCCCC2)=NOC=1C1CC1 AOSKTTCCMBUQAB-UHFFFAOYSA-N 0.000 description 2
- YVUIEZQZGJPTBJ-UHFFFAOYSA-N tert-butyl 3-[[5-cyclopropyl-3-(2-phenylcyclopropyl)-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2OCC=1C(C2C(C2)C=2C=CC=CC=2)=NOC=1C1CC1 YVUIEZQZGJPTBJ-UHFFFAOYSA-N 0.000 description 2
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 125000000260 trans-2-phenylcyclopropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])[C@]1([H])C([H])([H])[C@@]1([H])* 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- TYJRXMZXDBSURR-UWVGGRQHSA-N (1r,2r)-2-phenylcyclopropane-1-carbaldehyde Chemical compound O=C[C@@H]1C[C@H]1C1=CC=CC=C1 TYJRXMZXDBSURR-UWVGGRQHSA-N 0.000 description 1
- HUVJEFUEIFDUPF-DMTCNVIQSA-N (1s,2s)-2-(trifluoromethyl)cyclopropane-1-carbaldehyde Chemical compound FC(F)(F)[C@H]1C[C@@H]1C=O HUVJEFUEIFDUPF-DMTCNVIQSA-N 0.000 description 1
- RMEACWADEPTZOU-NTMALXAHSA-N (1z)-n-hydroxy-2-methylbenzenecarboximidoyl chloride Chemical compound CC1=CC=CC=C1\C(Cl)=N\O RMEACWADEPTZOU-NTMALXAHSA-N 0.000 description 1
- OBETXYAYXDNJHR-SSDOTTSWSA-M (2r)-2-ethylhexanoate Chemical compound CCCC[C@@H](CC)C([O-])=O OBETXYAYXDNJHR-SSDOTTSWSA-M 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- WKAHDSGGNJHYNS-PEZBUJJGSA-N (4z)-5-cyclopropyl-n-hydroxy-3-(2-methylphenyl)-1,2-oxazole-4-carboximidoyl chloride Chemical compound CC1=CC=CC=C1C1=NOC(C2CC2)=C1\C(Cl)=N\O WKAHDSGGNJHYNS-PEZBUJJGSA-N 0.000 description 1
- QTIUOCJOADSORK-UHFFFAOYSA-N (5-cyclopropyl-3-spiro[2.5]octan-6-yl-1,2-oxazol-4-yl)methanol Chemical compound OCC1=C(C2CC2)ON=C1C(CC1)CCC21CC2 QTIUOCJOADSORK-UHFFFAOYSA-N 0.000 description 1
- SZPFFHINHJINFU-UHFFFAOYSA-N (5-cyclopropyl-3-spiro[2.5]octan-8-yl-1,2-oxazol-4-yl)methanol Chemical compound OCC1=C(C2CC2)ON=C1C1CCCCC11CC1 SZPFFHINHJINFU-UHFFFAOYSA-N 0.000 description 1
- UXINFJXJHUADPI-DHZHZOJOSA-N (6e)-n-hydroxyspiro[2.5]octane-6-carboximidoyl chloride Chemical compound C1CC(C(\Cl)=N/O)CCC11CC1 UXINFJXJHUADPI-DHZHZOJOSA-N 0.000 description 1
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VTWKXBJHBHYJBI-VURMDHGXSA-N (nz)-n-benzylidenehydroxylamine Chemical compound O\N=C/C1=CC=CC=C1 VTWKXBJHBHYJBI-VURMDHGXSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- PEAQWZZFHDUADY-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-6-ylmethanol Chemical compound OCC1CCCCC11OCCO1 PEAQWZZFHDUADY-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- 229940044613 1-propanol Drugs 0.000 description 1
- XSHFQVMIVZWTQL-UHFFFAOYSA-N 2,3,4-trimethylpentan-3-yl acetate Chemical compound CC(C)C(C)(C(C)C)OC(C)=O XSHFQVMIVZWTQL-UHFFFAOYSA-N 0.000 description 1
- WDBAXYQUOZDFOJ-UHFFFAOYSA-N 2,3-difluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1F WDBAXYQUOZDFOJ-UHFFFAOYSA-N 0.000 description 1
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
- QOJQBWSZHCKOLL-UHFFFAOYSA-N 2,6-dimethylbenzaldehyde Chemical compound CC1=CC=CC(C)=C1C=O QOJQBWSZHCKOLL-UHFFFAOYSA-N 0.000 description 1
- LGSSKDOYOOTHFI-UHFFFAOYSA-N 2-(phenylmethoxymethyl)cyclohexan-1-one Chemical compound O=C1CCCCC1COCC1=CC=CC=C1 LGSSKDOYOOTHFI-UHFFFAOYSA-N 0.000 description 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 description 1
- RAGWFGSHOZGADV-UHFFFAOYSA-N 2-(trifluoromethyl)cyclohexane-1-carboxylic acid Chemical compound OC(=O)C1CCCCC1C(F)(F)F RAGWFGSHOZGADV-UHFFFAOYSA-N 0.000 description 1
- BFROETNLEIAWNO-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1C(F)(F)F BFROETNLEIAWNO-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- ZFABPPRPLMHARN-UHFFFAOYSA-N 2-[3-[[5-cyclopropyl-3-(2-phenylcyclopropyl)-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-1,3-benzothiazole-6-carboxylic acid Chemical compound S1C2=CC(C(=O)O)=CC=C2N=C1N1C(C2)CCC1CC2OCC=1C(C2C(C2)C=2C=CC=CC=2)=NOC=1C1CC1 ZFABPPRPLMHARN-UHFFFAOYSA-N 0.000 description 1
- CGVCVEZDFSKMOM-UHFFFAOYSA-N 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-4-methoxy-1,3-benzothiazole-6-carboxylic acid Chemical compound N=1C=2C(OC)=CC(C(O)=O)=CC=2SC=1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F CGVCVEZDFSKMOM-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- OACPOWYLLGHGCR-UHFFFAOYSA-N 2-chloro-6-fluorobenzaldehyde Chemical compound FC1=CC=CC(Cl)=C1C=O OACPOWYLLGHGCR-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- ZVDXHSUCDWVQEY-UHFFFAOYSA-N 2-cyclopropylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1CC1 ZVDXHSUCDWVQEY-UHFFFAOYSA-N 0.000 description 1
- QNJAZNNWHWYOEO-UHFFFAOYSA-N 2-ethylheptan-1-ol Chemical compound CCCCCC(CC)CO QNJAZNNWHWYOEO-UHFFFAOYSA-N 0.000 description 1
- BVKQLNXPPQEELX-UHFFFAOYSA-N 2-fluoro-4-iodo-5-methylpyridine Chemical compound CC1=CN=C(F)C=C1I BVKQLNXPPQEELX-UHFFFAOYSA-N 0.000 description 1
- BGQBJWPZBBMKEI-UHFFFAOYSA-N 2-fluoro-6-methylbenzaldehyde Chemical compound CC1=CC=CC(F)=C1C=O BGQBJWPZBBMKEI-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- FOEMIZSFFWGXHX-UHFFFAOYSA-N 2-methylsulfanylpyrimidine Chemical compound CSC1=NC=CC=N1 FOEMIZSFFWGXHX-UHFFFAOYSA-N 0.000 description 1
- OIGXNHYFKZCTCH-UHFFFAOYSA-N 2-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=NC=CC=N1 OIGXNHYFKZCTCH-UHFFFAOYSA-N 0.000 description 1
- POROIMOHDIEBBO-UHFFFAOYSA-M 2-oxocyclohexane-1-carboxylate Chemical compound [O-]C(=O)C1CCCCC1=O POROIMOHDIEBBO-UHFFFAOYSA-M 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- HXQRAQKAGXRFEM-UHFFFAOYSA-N 3-bromo-4-fluorobenzenethiol Chemical compound FC1=CC=C(S)C=C1Br HXQRAQKAGXRFEM-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- WVZBIQSKLXJFNX-UHFFFAOYSA-N 3-fluoro-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 WVZBIQSKLXJFNX-UHFFFAOYSA-N 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
- ASFHDLDAWYTMJS-UHFFFAOYSA-N 3-methoxypyridazine Chemical compound COC1=CC=CN=N1 ASFHDLDAWYTMJS-UHFFFAOYSA-N 0.000 description 1
- NNKLICLIBKMDOY-UHFFFAOYSA-N 3-methylidenecyclobutane-1-carboxylic acid Chemical compound OC(=O)C1CC(=C)C1 NNKLICLIBKMDOY-UHFFFAOYSA-N 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YCJJWXPLEWSYFQ-UHFFFAOYSA-N 4,6,6-trimethylbicyclo[3.1.1]heptane-3-carboxylic acid Chemical compound C1C(C(O)=O)C(C)C2C(C)(C)C1C2 YCJJWXPLEWSYFQ-UHFFFAOYSA-N 0.000 description 1
- MOOBKQQCTKSJQM-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-3-(2-chloro-6-fluorophenyl)-5-cyclopropyl-1,2-oxazole Chemical compound FC1=CC=CC(Cl)=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 MOOBKQQCTKSJQM-UHFFFAOYSA-N 0.000 description 1
- QKKXIEZBHXUNSU-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-3-(2-chlorophenyl)-5-cyclopropyl-1,2-oxazole Chemical compound ClC1=CC=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 QKKXIEZBHXUNSU-UHFFFAOYSA-N 0.000 description 1
- KXYHJWZWVPEIQB-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(2,3-difluorophenyl)-1,2-oxazole Chemical compound FC1=CC=CC(C=2C(=C(C3CC3)ON=2)COC2CC3CCC(N3)C2)=C1F KXYHJWZWVPEIQB-UHFFFAOYSA-N 0.000 description 1
- VOSOFQRJRVWTEB-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(2,4-difluorophenyl)-1,2-oxazole Chemical compound FC1=CC(F)=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 VOSOFQRJRVWTEB-UHFFFAOYSA-N 0.000 description 1
- WLRWIBXAFREVRO-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(2,6-difluorophenyl)-1,2-oxazole Chemical compound FC1=CC=CC(F)=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 WLRWIBXAFREVRO-UHFFFAOYSA-N 0.000 description 1
- WIEVMTNWHPFTKI-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(2,6-dimethylphenyl)-1,2-oxazole Chemical compound CC1=CC=CC(C)=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 WIEVMTNWHPFTKI-UHFFFAOYSA-N 0.000 description 1
- WTRUIIMHUUZFRU-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(2-fluoro-6-methylphenyl)-1,2-oxazole Chemical compound CC1=CC=CC(F)=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 WTRUIIMHUUZFRU-UHFFFAOYSA-N 0.000 description 1
- GAQICNZWKPOMGN-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(2-fluorophenyl)-1,2-oxazole Chemical compound FC1=CC=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 GAQICNZWKPOMGN-UHFFFAOYSA-N 0.000 description 1
- JGOVPOHODSHOKO-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(3,4-difluorophenyl)-1,2-oxazole Chemical compound C1=C(F)C(F)=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 JGOVPOHODSHOKO-UHFFFAOYSA-N 0.000 description 1
- XGXVLFKKNFQARI-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(3-fluorophenyl)-1,2-oxazole Chemical compound FC1=CC=CC(C=2C(=C(C3CC3)ON=2)COC2CC3CCC(N3)C2)=C1 XGXVLFKKNFQARI-UHFFFAOYSA-N 0.000 description 1
- RQJKJYWXIRHUGI-UHFFFAOYSA-N 4-(8-azabicyclo[3.2.1]octan-3-yloxymethyl)-5-cyclopropyl-3-(4,4-dimethylcyclohexyl)-1,2-oxazole Chemical compound C1CC(C)(C)CCC1C1=NOC(C2CC2)=C1COC1CC(N2)CCC2C1 RQJKJYWXIRHUGI-UHFFFAOYSA-N 0.000 description 1
- DEZDVAAAZZONAM-UHFFFAOYSA-N 4-(bromomethyl)-5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound FC(F)(F)OC1=CC=CC=C1C1=NOC(C2CC2)=C1CBr DEZDVAAAZZONAM-UHFFFAOYSA-N 0.000 description 1
- RXHPNUFKKACGCS-UHFFFAOYSA-N 4-(chloromethyl)-3,5-dicyclopropyl-1,2-oxazole Chemical compound ClCC=1C(C2CC2)=NOC=1C1CC1 RXHPNUFKKACGCS-UHFFFAOYSA-N 0.000 description 1
- FVRZELIWVUXDRT-UHFFFAOYSA-N 4-(chloromethyl)-5-cyclopropyl-3-(2-methylcyclopropyl)-1,2-oxazole Chemical compound CC1CC1C1=NOC(C2CC2)=C1CCl FVRZELIWVUXDRT-UHFFFAOYSA-N 0.000 description 1
- GXLZMFGUAUNMGT-UHFFFAOYSA-N 4-(chloromethyl)-5-cyclopropyl-3-[2-(trifluoromethyl)cyclopropyl]-1,2-oxazole Chemical compound FC(F)(F)C1CC1C1=NOC(C2CC2)=C1CCl GXLZMFGUAUNMGT-UHFFFAOYSA-N 0.000 description 1
- FJCNZJVJLMPUCX-UHFFFAOYSA-N 4-(chloromethyl)-5-cyclopropyl-3-spiro[2.5]octan-6-yl-1,2-oxazole Chemical compound ClCC1=C(C2CC2)ON=C1C(CC1)CCC21CC2 FJCNZJVJLMPUCX-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical compound [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
- VTAZCYUFVHFTJS-UHFFFAOYSA-N 5-cyclopropyl-3-(4,4-dimethylcyclohexyl)-1,2-oxazole-4-carboxylic acid Chemical compound C1CC(C)(C)CCC1C1=NOC(C2CC2)=C1C(O)=O VTAZCYUFVHFTJS-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- CTIULVWBXFFROZ-UHFFFAOYSA-N 6-cyclopropyl-2-methylsulfanylpyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=NC(SC)=NC(C2CC2)=C1 CTIULVWBXFFROZ-UHFFFAOYSA-N 0.000 description 1
- WFTSDXDUCJDEPT-UHFFFAOYSA-N 6-cyclopropyl-2-methylsulfonylpyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=NC(S(=O)(=O)C)=NC(C2CC2)=C1 WFTSDXDUCJDEPT-UHFFFAOYSA-N 0.000 description 1
- PHENIYTVOJTIOS-UHFFFAOYSA-N 6-fluoro-2-methylpyridine-3-carboxylic acid Chemical compound CC1=NC(F)=CC=C1C(O)=O PHENIYTVOJTIOS-UHFFFAOYSA-N 0.000 description 1
- RAJXDAPUJXFMQM-UHFFFAOYSA-N 8-(phenylmethoxymethyl)spiro[2.5]octane Chemical compound C1CCCC2(CC2)C1COCC1=CC=CC=C1 RAJXDAPUJXFMQM-UHFFFAOYSA-N 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 102100028163 ATP-binding cassette sub-family C member 4 Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000230 African Trypanosomiasis Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000014997 Crohn colitis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000030306 Eye degenerative disease Diseases 0.000 description 1
- ZYAKHFDLHJLEPJ-UHFFFAOYSA-N FICl Chemical compound FICl ZYAKHFDLHJLEPJ-UHFFFAOYSA-N 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000986629 Homo sapiens ATP-binding cassette sub-family C member 4 Proteins 0.000 description 1
- 101000846394 Homo sapiens Fibroblast growth factor 19 Proteins 0.000 description 1
- 101000955481 Homo sapiens Phosphatidylcholine translocator ABCB4 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102220470475 L-seryl-tRNA(Sec) kinase_C57L_mutation Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000236488 Lepra Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 206010024641 Listeriosis Diseases 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 101000946797 Mus musculus C-C motif chemokine 9 Proteins 0.000 description 1
- 241000187488 Mycobacterium sp. Species 0.000 description 1
- HRNRLZXUEATHMK-UHFFFAOYSA-N N-(spiro[2.5]octan-6-ylmethylidene)hydroxylamine Chemical compound C1CC(C=NO)CCC11CC1 HRNRLZXUEATHMK-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000034827 Neointima Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 101710202677 Non-specific lipid-transfer protein Proteins 0.000 description 1
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 1
- 101710105538 Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102100039032 Phosphatidylcholine translocator ABCB4 Human genes 0.000 description 1
- 102100022428 Phospholipid transfer protein Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001253201 Pineda Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000017855 Progressive familial intrahepatic cholestasis type 1 Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- RVUSHRYPVUVJMG-UHFFFAOYSA-N [3-(4-bicyclo[4.1.0]heptanyl)-5-cyclopropyl-1,2-oxazol-4-yl]methanol Chemical compound O1N=C(C2CC3CC3CC2)C(CO)=C1C1CC1 RVUSHRYPVUVJMG-UHFFFAOYSA-N 0.000 description 1
- VFBHEMMKMWLBOL-UHFFFAOYSA-N [5-cyclopropyl-3-(2-phenylcyclopropyl)-1,2-oxazol-4-yl]methanol Chemical compound OCC=1C(C2C(C2)C=2C=CC=CC=2)=NOC=1C1CC1 VFBHEMMKMWLBOL-UHFFFAOYSA-N 0.000 description 1
- FQLLHMQANRRXKX-UHFFFAOYSA-N [5-cyclopropyl-3-(4,4-dimethylcyclohexyl)-1,2-oxazol-4-yl]methanol Chemical compound C1CC(C)(C)CCC1C1=NOC(C2CC2)=C1CO FQLLHMQANRRXKX-UHFFFAOYSA-N 0.000 description 1
- JYNQOJCHCISPMT-ONGXEEELSA-N [5-cyclopropyl-3-[(1s,2s)-2-(trifluoromethyl)cyclohexyl]-1,2-oxazol-4-yl]methanol Chemical compound OCC=1C([C@@H]2[C@H](CCCC2)C(F)(F)F)=NOC=1C1CC1 JYNQOJCHCISPMT-ONGXEEELSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001341 alkaline earth metal compounds Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- IAHMNSCQDXESII-UHFFFAOYSA-N benzenecarboximidoyl chloride Chemical compound ClC(=N)C1=CC=CC=C1 IAHMNSCQDXESII-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WFRDCXXZMJFGCL-UHFFFAOYSA-N bicyclo[4.1.0]heptane-4-carboxylic acid Chemical compound C1C(C(=O)O)CCC2CC21 WFRDCXXZMJFGCL-UHFFFAOYSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940043430 calcium compound Drugs 0.000 description 1
- 150000001674 calcium compounds Chemical class 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 230000031154 cholesterol homeostasis Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000012085 chronic inflammatory response Effects 0.000 description 1
- 238000003181 co-melting Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- VUSWCWPCANWBFG-UHFFFAOYSA-N cyclohex-3-ene-1-carboxylic acid Chemical compound OC(=O)C1CCC=CC1 VUSWCWPCANWBFG-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000012969 defense response to bacterium Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001729 effect on metabolism Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethanedisulfonate group Chemical group C(CS(=O)(=O)[O-])S(=O)(=O)[O-] AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- IORWYWLTWOGJGX-UHFFFAOYSA-N ethyl 2-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-1,3-benzothiazole-6-carboxylate Chemical compound S1C2=CC(C(=O)OCC)=CC=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F IORWYWLTWOGJGX-UHFFFAOYSA-N 0.000 description 1
- DLVGFWIRQAUWDC-UHFFFAOYSA-N ethyl 4-methylidenecyclohexane-1-carboxylate Chemical compound CCOC(=O)C1CCC(=C)CC1 DLVGFWIRQAUWDC-UHFFFAOYSA-N 0.000 description 1
- MKBUGAITXRRPDD-UHFFFAOYSA-N ethyl 6-bromo-1-methylindazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=NN(C)C2=C1 MKBUGAITXRRPDD-UHFFFAOYSA-N 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000009866 extrahepatic cholestasis Diseases 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 208000029080 human African trypanosomiasis Diseases 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003317 industrial substance Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 208000001024 intrahepatic cholestasis Diseases 0.000 description 1
- 230000007872 intrahepatic cholestasis Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- NOCGROPYCGRERZ-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 NOCGROPYCGRERZ-UHFFFAOYSA-M 0.000 description 1
- LWSZWWSRHDIBHR-RNFRBKRXSA-N methyl (1r,2r)-2-(trifluoromethyl)cyclohexane-1-carboxylate Chemical compound COC(=O)[C@@H]1CCCC[C@H]1C(F)(F)F LWSZWWSRHDIBHR-RNFRBKRXSA-N 0.000 description 1
- LUQQRDSMUWWQSH-UHFFFAOYSA-N methyl 1,4-dioxaspiro[4.5]decane-6-carboxylate Chemical compound COC(=O)C1CCCCC11OCCO1 LUQQRDSMUWWQSH-UHFFFAOYSA-N 0.000 description 1
- QOGGWMGKEDUVML-UHFFFAOYSA-N methyl 2-[[2-[3-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octan-8-yl]-1,3-benzothiazole-6-carbonyl]amino]acetate Chemical compound S1C2=CC(C(=O)NCC(=O)OC)=CC=C2N=C1N1C(C2)CCC1CC2OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F QOGGWMGKEDUVML-UHFFFAOYSA-N 0.000 description 1
- XSEAGAYSAHNOQI-UHFFFAOYSA-N methyl 2-bromo-4-methyl-1,3-benzothiazole-6-carboxylate Chemical compound COC(=O)C1=CC(C)=C2N=C(Br)SC2=C1 XSEAGAYSAHNOQI-UHFFFAOYSA-N 0.000 description 1
- UOUBEKSUNCCLDY-UHFFFAOYSA-N methyl 2-chloroquinoline-6-carboxylate Chemical compound N1=C(Cl)C=CC2=CC(C(=O)OC)=CC=C21 UOUBEKSUNCCLDY-UHFFFAOYSA-N 0.000 description 1
- OSWTXCSCDKIANQ-UHFFFAOYSA-N methyl 3-methylidenecyclobutane-1-carboxylate Chemical compound COC(=O)C1CC(=C)C1 OSWTXCSCDKIANQ-UHFFFAOYSA-N 0.000 description 1
- AIUWAOALZYWQBX-UHFFFAOYSA-N methyl 4-amino-3-bromobenzoate Chemical compound COC(=O)C1=CC=C(N)C(Br)=C1 AIUWAOALZYWQBX-UHFFFAOYSA-N 0.000 description 1
- DJLFOMMCQBAMAA-UHFFFAOYSA-N methyl 4-amino-3-methoxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(OC)=C1 DJLFOMMCQBAMAA-UHFFFAOYSA-N 0.000 description 1
- ZHIPSMIKSRYZFV-UHFFFAOYSA-N methyl 4-amino-3-methylbenzoate Chemical compound COC(=O)C1=CC=C(N)C(C)=C1 ZHIPSMIKSRYZFV-UHFFFAOYSA-N 0.000 description 1
- WINGWVOUOFMOJQ-UHFFFAOYSA-N methyl 5-bromo-6-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C(Br)=C1 WINGWVOUOFMOJQ-UHFFFAOYSA-N 0.000 description 1
- UTZREDGZLNYDIQ-UHFFFAOYSA-N methyl 5-cyclopropyl-3-(2-methylphenyl)-1,2-oxazole-4-carboxylate Chemical compound COC(=O)C1=C(C2CC2)ON=C1C1=CC=CC=C1C UTZREDGZLNYDIQ-UHFFFAOYSA-N 0.000 description 1
- ZZKLQEFSZHSBGS-UHFFFAOYSA-N methyl 5-cyclopropyl-3-(4,4-dimethylcyclohexyl)-1,2-oxazole-4-carboxylate Chemical compound COC(=O)C=1C(C2CCC(C)(C)CC2)=NOC=1C1CC1 ZZKLQEFSZHSBGS-UHFFFAOYSA-N 0.000 description 1
- XAQQCRZZJQJAAP-UHFFFAOYSA-N methyl 5-cyclopropyl-3-spiro[2.3]hexan-5-yl-1,2-oxazole-4-carboxylate Chemical compound COC(=O)C=1C(C2CC3(CC3)C2)=NOC=1C1CC1 XAQQCRZZJQJAAP-UHFFFAOYSA-N 0.000 description 1
- LREJBRSZBHRONZ-UHFFFAOYSA-N methyl 6-bromo-5-fluoro-1,2-benzothiazole-3-carboxylate Chemical compound BrC1=C(F)C=C2C(C(=O)OC)=NSC2=C1 LREJBRSZBHRONZ-UHFFFAOYSA-N 0.000 description 1
- BQVXASUNSLLUGY-UHFFFAOYSA-N methyl 6-chloro-4-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CN=C(Cl)C=C1C BQVXASUNSLLUGY-UHFFFAOYSA-N 0.000 description 1
- ZZMFUYBAZICPHP-UHFFFAOYSA-N methyl 6-cyclopropyl-2-methylsulfonylpyrimidine-4-carboxylate Chemical compound CS(=O)(=O)C1=NC(C(=O)OC)=CC(C2CC2)=N1 ZZMFUYBAZICPHP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JQWVYSYQJRMDHG-UHFFFAOYSA-N methyl quinoline-5-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CC=CC2=N1 JQWVYSYQJRMDHG-UHFFFAOYSA-N 0.000 description 1
- XSRWQTDEIOHXSL-UHFFFAOYSA-N methyl quinoline-6-carboxylate Chemical compound N1=CC=CC2=CC(C(=O)OC)=CC=C21 XSRWQTDEIOHXSL-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ZMULZVILNURIQY-UHFFFAOYSA-N n-[[2-(trifluoromethoxy)phenyl]methylidene]hydroxylamine Chemical compound ON=CC1=CC=CC=C1OC(F)(F)F ZMULZVILNURIQY-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PEDXWXAHCZOUDT-UHFFFAOYSA-N n-hydroxyspiro[2.3]hexane-5-carboximidoyl chloride Chemical compound C1C(C(Cl)=NO)CC11CC1 PEDXWXAHCZOUDT-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 230000008692 neointimal formation Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000002612 sleeping sickness Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- LQPGRYWUUGVTPV-UHFFFAOYSA-N spiro[2.5]octane-6-carbaldehyde Chemical compound C1CC(C=O)CCC11CC1 LQPGRYWUUGVTPV-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229950009390 symclosene Drugs 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- AGSTZSPSZBSEFG-UHFFFAOYSA-N tert-butyl 3-[(5-cyclopropyl-3-spiro[2.3]hexan-5-yl-1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2OCC=1C(C2CC3(CC3)C2)=NOC=1C1CC1 AGSTZSPSZBSEFG-UHFFFAOYSA-N 0.000 description 1
- BRMAUPBUPKPECV-UHFFFAOYSA-N tert-butyl 3-[[3-(6-bicyclo[3.1.0]hexanyl)-5-cyclopropyl-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2OCC=1C(C2C3CCCC32)=NOC=1C1CC1 BRMAUPBUPKPECV-UHFFFAOYSA-N 0.000 description 1
- QGNIFUNTYCYAHW-UHFFFAOYSA-N tert-butyl 3-[[5-cyclopropyl-3-(1-methyl-6-bicyclo[3.1.0]hexanyl)-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2OCC=1C(C2C3(CCCC32)C)=NOC=1C1CC1 QGNIFUNTYCYAHW-UHFFFAOYSA-N 0.000 description 1
- VXPNZKCXTOIWFQ-UHFFFAOYSA-N tert-butyl 3-[[5-cyclopropyl-3-(2-methylphenyl)-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC1=CC=CC=C1C1=NOC(C2CC2)=C1COC1CC(N2C(=O)OC(C)(C)C)CCC2C1 VXPNZKCXTOIWFQ-UHFFFAOYSA-N 0.000 description 1
- OXCIFCMSBIIKMA-UHFFFAOYSA-N tert-butyl 3-[[5-cyclopropyl-3-(4,4-dimethylcyclohexyl)-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2OCC=1C(C2CCC(C)(C)CC2)=NOC=1C1CC1 OXCIFCMSBIIKMA-UHFFFAOYSA-N 0.000 description 1
- VXQHBWSRBUSCMZ-UHFFFAOYSA-N tert-butyl 3-[[5-cyclopropyl-3-(4,6,6-trimethyl-3-bicyclo[3.1.1]heptanyl)-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC1C(C2(C)C)CC2CC1C(C=1COC2CC3CCC(N3C(=O)OC(C)(C)C)C2)=NOC=1C1CC1 VXQHBWSRBUSCMZ-UHFFFAOYSA-N 0.000 description 1
- BWEMHBKAOXSVPN-UHFFFAOYSA-N tert-butyl 3-[[5-cyclopropyl-3-[2-(trifluoromethyl)cyclohexyl]-1,2-oxazol-4-yl]methoxy]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C2)CCC1CC2OCC=1C(C2C(CCCC2)C(F)(F)F)=NOC=1C1CC1 BWEMHBKAOXSVPN-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000012443 tonicity enhancing agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000002311 trypanosomiasis Diseases 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000010518 undesired secondary reaction Methods 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
Definitions
- the present invention relates to compositions and methods for modulating the activity of farnesoid X receptors (FXRs).
- FXRs farnesoid X receptors
- the farnesoid X receptor is a member of the nuclear hormone receptor superfamily and is primarily expressed in the liver, kidney and intestine (see, e.g., Seol et al. (1995) Mol. Endocrinol. 9:72-85 and Forman et al. (1995) Cell 81:687-693). It functions as a heterodimer with the retinoid X receptor (RXR) and binds to response elements in the promoters of target genes to regulate gene transcription.
- RXR retinoid X receptor
- the FXR-RXR heterodimer binds with highest affinity to an inverted repeat- 1 (IR-1) response element, in which consensus receptor-binding hexamers are separated by one nucleotide.
- FXR is part of an interrelated process, in that FXR is activated by bile acids (the end product of cholesterol metabolism) (see, e.g., Makishima et al.
- FXR is a key regulator of cholesterol homeostasis, triglyceride synthesis and lipogenesis.
- Crawley, Expert Opinion Ther. Patents (2010), 20(8): 1047-1057 In addition to the treatment of dyslipidemia, multiple indications for FXR have been described, including treatment of liver disease, diabetes, vitamin D-related diseases, drug-induced side effects and hepatits. (Crawley, supra). While advances have been made in the development of novel FXR agonists, significant room for improvement remains. It is the object of the present invention to provide novel compounds that are agonists or partial agonists of FXR exhibiting
- ADME adsorption, distribution, metabolism and excretion
- the present invention relates to compositions and methods for modulating the activity of farnesoid X receptors (FXRs).
- FXRs farnesoid X receptors
- the present invention relates to compounds which act as agonists or partial agonists of FXR.
- Z is phenylene, C 5 _7 cycloalkylene or 5-10 membered monocyclic or bicyclic heteroaryl containing 1-2 heteroatoms selected from N, O and S; each of which is optionally substituted with 1-2 R 6 radicals selected from halogen, C 1-6 alkyl, haloCi-6 alkyl, C 1-6 alkoxy, haloCi-6 alkoxy, or cyclopropyl;
- R 1 is phenyl, pyridyl, bicyclo[3.1.0]hexanyl, spiro[2.3]hexanyl, bicyclo[3.1.1]heptanyl, spiro[2.5]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexan-6-yl, spiro[2.3]hexan-5-yl, bicyclo[3.1.1]heptan-3-yl, spiro[2.5]octan-4-yl, bicyclo[4.1.0]heptan-3-yl, cyclohexyl or cyclopentyl, each of which is optionally substituted with 1-3 R la ; or R 1 is cyclopropyl optionally substituted with 1-2 R la or phenyl;
- R la is halogen, Ci_6 alkyl, haloC ⁇ alkyl, Ci_6 alkoxy, haloC ⁇ alkoxy or cyclopropyl;
- R is Ci-3 alkyl, haloCi-3 alkyl or cyclopropyl optionally substituted with C 1-3 alkyl or haloCi-3 alkyl;
- R 3 is -X-CO 2 R 4 , hydroxyCi_ 6 alkyl, CONR 4 R 5 , CONR(CR 2 ) w C0 2 R 4 , CONR(CR 2 )i_ 4 S0 3 R 5 or tetrazolyl; wherein X is a bond, C 1-2 alkylene or cyclopropyl; and
- R, R 4 and R 5 are independently hydrogen or C 1-6 alkyl.
- the compounds of the invention are defined by Formula (I) wherein R is cyclopropyl.
- the compounds of the invention are defined by Formula (I) in any of the first or second embodiments, wherein Z is phenylene, pyridylene, pyrimidinylene, pyrazinylene, pyridazinylene, thiazolylene, benzothiazolyl, benzo[d]isothiazolyl, imidazo[l,2- a]pyridinyl, quinolinyl, lH-indolyl, pyrrolo[l,2-b]pyridazinyl, benzofuranyl,
- the compounds of the invention are selected from the group consisting of:
- R 1 , R 3 and R 6 are as defined in Formula (I).
- the compounds of the invention are selected from the group consisting of:
- R 1 , R 3 and R 6 are as defined in Formula (I).
- the compounds of the invention are selected from the group consisting of:
- X 1 and X 2 are independently N, CH or CR 6 ;
- X 3 is O or S
- R 6 may be attached to any position in the ring
- n 0-1; and R 1 , R 3 and R 6 are as defined in Formula (I).
- the compounds of the invention are defined by Formula (I) and (IA)-(IY) in any of the above embodiments, wherein R 1 is phenyl substituted with 1-3 R la ; and R la is halogen, C 1-6 alkyl, haloC ⁇ alkyl, C 1-6 alkoxy, haloCi-6 alkoxy.
- R 1 is phenyl substituted with 1-3 R la ; and R la is halogen, C 1-6 alkyl, haloC ⁇ alkyl, C 1-6 alkoxy, haloCi-6 alkoxy.
- the compounds of the invention are defined by Formula (I) and (IA)-(IY) in any of the above embodiments, wherein R 3 is -X-C0 2 R 4 ; X is a bond and R 4 is hydrogen or C 1-6 alkyl.
- the compounds of the invention are defined by Formula (I) and (IA)-(IY) in any of the above embodiments, wherein R 6 is methyl, methoxy, fluoro or trifluoromethoxy.
- the invention provides a glycine conjugate of a compound of the invention.
- the invention provides a taurine conjugate of a compound of the invention.
- the invention provides an acylglucuronide conjugate of a compound of the invention.
- the present invention also provides a compound having Formula (III)
- R 1 and R 2 are as defined in Formula (I); or a pharmaceutically acceptable salt thereof.
- R in Formula (III) is cyclopropyl.
- the present invention provides a process for preparing a compound of Formula (I), comprising reacting a compound of Formula (III) with a compound of Y-Z-R ; wherein Y is a leaving group (such as chloro or bromo); and
- R 1 , R2 , R 3 and Z are as defined in Formula (I);
- C ealkyl denotes a an alkyl radical having from 1 up to 6, particularly up to 4 carbon atoms, the radicals being either linear or branched with single or multiple branching; for example, butyl, such as n-butyl, sec-butyl, isobutyl, tert-butyl; propyl, such as n-propyl or isopropyl; ethyl or methyl; more particularly, methyl, propyl or tert-butyl.
- Ci-3 alkyl refers to an alkyl radical as defined herein, containing one to three carbon atoms.
- alkylene refers to divalent alkyl group as defined herein above having a specified number of carbon atoms.
- Representative examples of alkylene include, but are not limited to, methylene, ethylene, n-propylene, iso-propylene, n-butylene, sec-butylene, iso-butylene, tert-butylene, and the like.
- C 3 _8 cycloalkyl refers to saturated or unsaturated monocyclic or bicyclic hydrocarbon groups of 3-8 carbon atoms (including spirocyclic rings).
- C 3 _g cycloalkyl as used herein may encompass monovalent and divalent cycloalkyls, which will be apparent to those skilled in the art.
- Exemplary monocyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl and the like, and monovalent or divalent forms thereof.
- bicyclic hydrocarbon groups include but are not limited to bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, 6,6- dimethylbicyclo[3.1. l]heptyl, 2,6,6-trimethylbicyclo[3.1.
- spirocyclic rings include but are not limited to spiro[2.5]octan-6-yl and the like, and monocyclic or divalent forms thereof.
- aryl refers to an aromatic hydrocarbon group having 6-20 carbon atoms in the ring portion. Typically, aryl is monocyclic, bicyclic or tricyclic aryl having 6-20 carbon atoms. Furthermore, the term “aryl” as used herein, refers to an aromatic substituent which can be a single aromatic ring, or multiple aromatic rings that are fused together; and may encompass monovalent and divalent aryls, which will be apparent to those skilled in the art. Non-limiting examples include phenyl, phenylene, naphthyl, naphthylene, tetrahydronaphthyl or tetrahydronaphthylene .
- heteroaryl refers to a 5-14 membered monocyclic- or bicyclic- or tricyclic-aromatic ring system having 1 to 8 heteroatoms.
- the heteroaryl is a 5-10 membered ring system (e.g., 5-7 membered monocycle or an 8-10 memberred bicycle) or a 5-7 membered ring system.
- the term “heteroaryl” as used herein may encompass monovalent or divalent heteroaryls, which will be apparent to those skilled in the art.
- Typical monocyclic heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5- imidazolyl, 3-, 4-, or 5- pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5- oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1,2,4-triazolyl, 4- or 5-1,2, 3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4-pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, and monovalent or divalent forms thereof.
- Typical bicyclic heteroaryl groups include benzofuranyl, benzo[d]isothiazolyl, benzo[d]isoxazolyl, benzothiazolyl, benzo[b]thiophenyl, imidazo[l,2- a]pyridinyl, imidazo[l,2-b]pyridazinyl, lH-indolyl, lH-indazolyl, pyrazolo[l,5-a]pyridinyl, pyrrolo[l,2-b]pyridazinyl, lH-pyrrolo[3,2-c]pyridinyl, pyrazolo[l,5-a]pyrimidinyl, quinazolinyl and the like, and monovalent or divalent forms thereof.
- Ci_6 alkoxy refers to Ci_6 alkyl-O-, and is particularly methoxy, ethoxy, isopropyloxy, or tert-butoxy.
- hydroxyC ⁇ alkyl refers to C 1-6 alkyl-OH, wherein C 1-6 alkyl is as defined above.
- the hydroxy group may be attached to the alkyl radical on any carbon within the alkyl radical, and is particularly hydroxymethyl, 2-hydroxyethyl or 2-hydroxy-2-propyl.
- halogen refers to fluoro, chloro, bromo, and iodo; and more particularly, fluoro or chloro.
- haloC ⁇ alkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, and is particularly fluoroCi-6 alkyl, more particularly trifluoromethyl.
- haloCi-ealkoxy refers to an alkoxy radical, as defined above, that is substituted by one or more halo radicals, as defined above, and is particularly fluoroCi-6 alkoxy, more particularly, trifluoromethoxy or difluoromethoxy.
- a “stereoisomer” refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
- the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are
- amino acid conjugate refers to conjugates of the compound of Formula I, (I- A) to (TY), ( ⁇ ), II, and (II-A)-(II-K)with any suitable amino acid.
- suitable amino acid conjugates of the compound of Formula I, (I- A) to (TY), (T), II, and (II-A)-(II-K) will have the added advantage of enhanced integrity in bile or intestinal fluids.
- suitable amino acids include but are not limited to glycine, taurine and acylglucuronide.
- the present invention encompasses the glycine, taurine and acylglucuronide conjugates of the compound of Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K).
- the term "pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289- 1329). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the therapeutic or pharmaceutical
- compositions is contemplated.
- the term "therapeutically effective amount” refers to an amount of the compound of Formula I, (I- A) to (TY), (T), II, and (II-A)-(II-K) which is sufficient to achieve the stated effect. Accordingly, a therapeutical effective amount of a compound of Formula I, (I- A) to (I-Y), (T), II, and (II-A)-(II-K) used in for the treatment of a condition mediated by FXR will be an amount sufficient for the treatment of the condition mediated by FXR.
- the term "subject” refers to an animal. Typically the animal is a mammal. A subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain embodiments, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like. In certain aspects of the animals are used herein.
- primates e.g., humans, male or female
- cows e.g., sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
- primates e.g., humans, male or female
- cows e.g., sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
- the subject is a primate. In yet other embodiments, the subject is a human.
- the term “treat”, “treating” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
- “treat”, “treating” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
- “treat”, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
- “treat”, “treating” or “treatment” refers to preventing or delaying the onset or development or progression of the disease or disorder.
- a subject is "in need of a treatment if such subject would benefit biologically, medically or in quality of life from such treatment.
- dyslipidemia refers to an abonormality in, or abrnomal amounts of lipids and lipoproteins in the blood and the disease states resulting, caused by, exacerbated by, or adjunct to such abnormality (see, Dorland's Illutrated Medical Dictionary, 29th edition, W.B. Saunders Publishing Company, New York, NY).
- Disease states encompassed within the definition of dyslipidemia as used herein include hyperlipidemia, hypertriglyceremia, low plasma HDL, high plasma LDL, high plasma VLDL, liver cholestasis, and
- disorders related to dyslipidemia refers to diseases including but not limited to atherosclerosis, thrombosis, coronary artery disease, stroke, and hypertension. Diseases related to dyslipidemia also include metabolic diseases such as obesity, diabetes, insulin resistance, and complications thereof.
- cholestasis refers to any condition in which the flow of bile from the liver is blocked, and may be intrahepatic (i.e., occurring inside the liver) or extrahepatic (i.e., occurring outside the liver).
- liver fibrosis includes liver fibrosis due to any cause, including but not limited to virally-induced liver fibrosis such as that due to hepatitis B and C; exposure to alcohol (alcoholic liver disease), pharmaceutical compounds, oxidative stress, cancer radiation therapy or industrial chemicals ; and diseases such as primary biliary cirrhosis, fatty liver, obesity, non-alcoholic steatohepatitis, cystic fibrosis, hemochromatosis, and auto-immune hepatitis.
- virally-induced liver fibrosis such as that due to hepatitis B and C
- alcohol alcoholic liver disease
- pharmaceutical compounds oxidative stress
- cancer radiation therapy or industrial chemicals oxidative stress
- diseases such as primary biliary cirrhosis, fatty liver, obesity, non-alcoholic steatohepatitis, cystic fibrosis, hemochromatosis, and auto-immune hepatitis.
- FXR agonist refers to an agent that directly binds to and upregulates the activity of FXR.
- the term “a,” “an,” “the” and similar terms used in the context of the present invention are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context.
- the present invention relates to compositions and methods for FXR.
- Various embodiments of the invention are described herein. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments.
- Z is phenylene, C 5 _7 cycloalkylene or 5-10 membered monocyclic or bicyclic heteroaryl containing 1-2 heteroatoms selected from N, O and S; each of which is optionally substituted with 1-2 R 6 radicals selected from halogen, C 1-6 alkyl, haloCi-6 alkyl, C 1-6 alkoxy, haloCi-6 alkoxy, or cyclopropyl;
- R 1 is phenyl, pyridyl, bicyclo[3.1.0]hexanyl, spiro[2.3]hexanyl, bicyclo[3.1.1]heptanyl, spiro[2.5]octanyl, bicyclo[4.1.0]heptanyl, bicyclo[3.1.0]hexan-6-yl, spiro[2.3]hexan-5-yl, bicyclo[3.1.1]heptan-3-yl, spiro[2.5]octan-4-yl, bicyclo[4.1.0]heptan-3-yl, cyclohexyl or cyclopentyl, each of which is optionally substituted with 1-3 R la ; or R 1 is cyclopropyl optionally substituted with 1-2 R la or phenyl;
- R la is halogen, C 1-6 alkyl, haloCi-6 alkyl, C 1-6 alkoxy, haloCi-6 alkoxy or cyclopropyl;
- R is C 1-3 alkyl, haloCi-3 alkyl or cyclopropyl optionally substituted with C 1-3 alkyl or haloCi-3 alkyl;
- R 3 is -X-CO2R 4 , hydroxyCi-6 alkyl, CONR 4 R 5 , CONR(CR 2 ) w C0 2 R 4 , CONR(CR 2 )i- 4 SO 3 R 5 or tetrazolyl; wherein X is a bond, C 1-2 alkylene or cyclopropyl; and
- R, R 4 and R 5 are independently hydrogen or C 1-6 alkyl.
- the compounds of the invention are selected from the group consisting of:
- R 1 , R 3 and R 6 are as defined in Formula (I).
- the compounds of the invention are selected from the group consisting of:
- R 1 , R 3 and R 6 are as defined in Formula (I).
- the compounds of the invention are selected from the group consisting of:
- X 1 and X 2 are independently N, CH or CR 6 ;
- X 3 is O or S
- R 6 may be attached to any position in the ring
- n 0-1; and R 1 , R 3 and R 6 are as defined in Formula (I).
- L is a bond, C 1-4 alkylene or Ci ⁇ alkylene-O-;
- Z is phenyl, C5-7 cycloalkyl or 5-10 membered monocyclic or bicyclic heteroaryl containing 1-2 heteroatoms selected from N, O and S; each of which is optionally substituted with 1-2 R 6 radicals selected from halogen, Ci_6 alkyl, haloC ⁇ alkyl, C 1-6 alkoxy, haloCi-6 alkoxy, cyclopropyl or NR 4 R 5 ;
- R 1 is phenyl substituted with 1-3 R la ; or R 1 is C3-8 cycloalkyl optionally substituted with 1-3 R la or phenyl;
- R la is halogen, Ci_6 alkyl, haloC ⁇ alkyl, Ci_6 alkoxy or haloC ⁇ alkoxy;
- R is Ci-3 alkyl, haloCi-3 alkyl or cyclopropyl optionally substituted with C 1-3 alkyl or haloCi-3 alkyl;
- R 3 is -X-CO 2 R 4 , hydroxyCi_ 6 alkyl, CONR 4 R 5 , CONR(CR 2 ) w C0 2 R 4 , CONR(CR 2 )i_ 4 S0 3 R 5 , cyano, tetrazolyl or S0 2 NR 4 R 5 ; wherein X is a bond or C 1-2 alkylene; and
- R 4 and R 5 are independently hydrogen or C 1-6 alkyl
- the compounds of the invention are defined by Formula ( ⁇ ), wherein L is a bond,-CH 2 - or -CH 2 -0-; and more particularly, wherein L is a bond.
- Z is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl or benzo[d]isothiazolyl; each of which is optionally substituted with 1-2 R 6 radicals selected from halogen, C 1-6 alkyl, haloCi-6 alkyl, C 1-6 alkoxy, haloCi-6 alkoxy, cyclopropyl or NR 4 R 5 ; R 1 is phenyl substituted with 1-3 R la ; or R 1 is C 3 _g cycloalkyl optionally substituted with 1-3 R la or phenyl;
- R la is halogen, C 1-6 alkyl, haloCi-6 alkyl, C 1-6 alkoxy or haloCi-6 alkoxy;
- R is C 1-3 alkyl, haloC 1-3 alkyl or cyclopropyl optionally substituted with C 1-3 alkyl or haloC 1-3 alkyl;
- R 3 is C0 2 R 4 , hydroxyCi_ 6 alkyl, CONR 4 R 5 , CONR(CR 2 )i_ 4 C0 2 R 4 , CONR(CR 2 )i_ 4 S0 3 R 5 or tetrazolyl; and
- R 4 and R 5 are independently hydrogen or C 1-6 alkyl
- the compounds of the invention are selected from the group consisting of:
- R 1 is phenyl substituted with 1-3 R la ; or R 1 is C3-8 cycloalkyl optionally substituted with 1-3 R la or phenyl;
- R la is halogen, Ci_6 alkyl, haloC ⁇ alkyl, Ci_6 alkoxy or haloC ⁇ alkoxy;
- R 3 is C0 2 R 4 , hydroxyCi_ 6 alkyl, CONR 4 R 5 , CONR(CR 2 )i- 4 C0 2 R 4 , CONR(CR 2 )i_ 4 S0 3 R 5 or tetrazolyl;
- R 4 and R 5 are independently hydrogen or C 1-6 alkyl
- R 6 is halogen, C 1-6 alkyl, haloCi-6 alkyl, C 1-6 alkoxy or haloCi-6 alkoxy;
- n 0-1;
- the invention provides a compound of Formula I, I-A, I-B, I- C, I-D, I-E, I-F, I-G, I-H, I-I, I-J, I-K, I-L, I-M, I-N, I-O, I-P, I-Q, I-R, I-S, I-T, I-U, I-V, I-W, I- X, I-Y, ( ⁇ ), II, II-A, II-B, II-C, II-D, II-E, II-F, II-G, II-H, II I, II-J or II-K (collectively, Formula I, (I-A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K)), wherein a substituent is defined, collectively or in any combination or sub-combination, as follows:
- Z is phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiazolyl or benzo[d]- isothiazolyl; each of which is optionally substituted with 1-2 R 6 radicals; and more particularly, Z is pyridyl, pyrimidinyl, pyrazinyl or benzothiazolyl, each of which is optionally substituted with 1-2 R 6 radicals;
- R 1 is phenyl substituted with 1-3 R la ; or R 1 is C 3 _g cycloalkyl optionally substituted with 1-3 R la or phenyl; particularly, R 1 is phenyl, spiro[2.5]octan-6-yl, bicyclo[3.1.0]hexan-6-yl, spiro[2.3]hexan-5-yl, bicyclo[3.1.1]heptan-3-yl, bicyclo[4.1.0]heptan-3-yl, cyclohexyl, cyclopentyl or norbonyl, each of which is optionally substituted with 1-3 R la ; or R 1 is cyclopropyl optionally substituted with 1-2 R la or phenyl; and more particularly, R 1 is phenyl or spiro[2.5]octan-6-yl, each of which is optionally substituted with 1-2 R la ;
- R la is halogen, Ci_6 alkyl, haloC ⁇ alkyl, Ci_6 alkoxy or haloC ⁇ alkoxy; particularly R la is fluoro, methyl, trifluoromethyl, trifluoromethoxy, difluoromethoxy or methoxy;
- R is Ci-3 alkyl, haloCi-3 alkyl or cyclopropyl optionally substituted with C 1-3 alkyl or haloCi-3 alkyl; and more particularly, R is cyclopropyl;
- R 3 is -X-CO 2 R 4 , hydroxyCi_ 6 alkyl, CONR 4 R 5 , CONR(CR 2 )i- 4 C0 2 R 4 , CONR(CR 2 )i_ 4 S0 3 R 5 , cyano, tetrazolyl or S0 2 NR 4 R 5 ; particularly, R 3 is -X-C0 2 R 4 , CONR(CR 2 )C0 2 R 4 , CONR(CR 2 ) 2 S0 3 R 5 ; and more particularly, R 3 is -X-C0 2 R 4 ; X is a bond and each R 4 and R 5 are independently hydrogen or C 1-6 alkyl;
- R 6 is selected halogen, Ci_6 alkyl, haloCi-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, cyclopropyl or NR 4 R 5 wherein R 4 and R 5 are independently hydrogen or C 1-6 alkyl; particularly, R 6 is selected from halo (particularly fluoro, chloro, bromo), C 1-6 alkyl (particularly methyl), haloCi-6 alkyl (particularly trifluoromethyl), C 1-6 alkoxy (particularly methoxy) or haloCi-6 alkoxy (particularly trifluoromethoxy); and more particularly, R 6 is methyl, methoxy, fluoro or trifluoromethoxy; and
- g) m is 0-2; and more particularly, m is 0-1.
- the present invention provides pharmaceutical compositions comprising a compound having Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K), and a pharmaceutically acceptable carrier.
- the present invention also provides a pharmaceutical composition comprising a compound of Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K) for use in the treatment of a condition mediated by FXR.
- the compounds of the invention are agonists of Farnesoid X receptors (FXRs), and are useful as pharmaceuticals to treat FXR-mediated conditions such as cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), primary sclerosing cholangistis (PSC), progressive familiar cholestatis (PFIC), non- alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), drug-induced bile duct injury, gallstones, liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, bile duct obstruction, cholelithiasis, liver fibrosis, dyslipidemia, atherosclerosis, diabetes, diabetic nephropathy, colitis,
- the invention provides methods for modulating FXR in a cell, comprising contacting the cell with an effective amount of a compound of Formula I, (I-A) to (I- Y), ( ⁇ ), II, and (II-A)-(II-K), or a pharmaceutical composition thereof.
- the invention provides methods to treat, ameliorate or prevent a FXR-mediated disorder in a subject suffering there from, comprising administering to the subject a therapeutically effective amount of a compound of Formula I, (I-A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K), or a pharmaceutical composition thereof, and optionally in combination with a second therapeutic agent.
- the present invention also provides for the use of a compound of Formula I, (I-A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K), and optionally in combination with a second therapeutic agent, in the manufacture of a medicament for treating a FXR-mediated disorder such as cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), primary sclerosing cholangistis (PSC), progressive familiar cholestatis (PFIC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), drug-induced bile duct injury, gallstones, liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, bile duct obstruction, cholelithias
- the present invention provides a combination comprising a therapeutically effective amount of a compound of Formula I, (I-A) to (I-Y), ( ⁇ ), II, and (II- A)- (II-K), and a second therapeutic agent being useful in the treatment of cholestasis, intrahepatic cholestatis, estrogen-induced cholestasis, drug-induced cholestasis, cholestasis of pregnancy, parenteral nutrition-associated cholestasis, primary biliary cirrhosis (PBC), primary sclerosing cholangistis (PSC), progressive familiar cholestatis (PFIC), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), drug-induced bile duct injury, gallstones, liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis, bile duct obstruction, cholelithiasis, liver
- PBC primary biliary
- the term "compounds of the present invention” refers to compounds of Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K), prodrugs thereof, salts of the compound and/or prodrugs, hydrates or solvates of the compounds, salts and/or prodrugs, as well as all stereoisomers (including diastereoisomers and enantiomers), tautomers and isotopically labeled compounds (including deuterium substitutions), as well as inherently formed moieties (e.g., polymorphs, solvates and/or hydrates).
- Certain of the compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the present invention is meant to include all possible isomers, including racemic mixtures, optically pure forms and intermediate mixtures.
- Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration. If the compound contains a disubstituted cycloalkyl, the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
- any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
- Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
- isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, n C, 13 C, 14 C, 15 N, 18 F, 31 P, 32 P, 35 S, 36 C1 and
- the invention includes various isotopically labeled compounds as defined herein, for example those into which radioactive isotopes, such as 3 H, 13 C, and 14 C , are present.
- isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
- Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
- substitution with heavier isotopes may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index.
- deuterium in this context is regarded as a substituent of a compound of Formula I, (I- A) to (TY), ( ⁇ ), II, and (II-A)-(II-K).
- concentration of such a heavier isotope, specifically deuterium may be defined by the isotopic enrichment factor.
- isotopic enrichment factor as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
- a substituent in a compound of this invention is denoted deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium
- incorporation at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
- Isotopically-labeled compounds of Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Processes using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.
- compositions in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 0, d 6 -acetone, d 6 - DMSO.
- Compounds of the invention i.e. compounds of Formula I, (I- A) to (TY), ( ⁇ ), II, and (II-A)-(II-K) that contain groups capable of acting as donors and/or acceptors for hydrogen bonds may be capable of forming co-crystals with suitable co-crystal formers.
- These co-crystals may be prepared from compounds of Formula I, (I-A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K) by known co-crystal forming procedures.
- Such procedures include grinding, heating, co-subliming, co-melting, or contacting in solution compounds of Formula I, (I-A) to (I-Y), ( ⁇ ), II, and (II- A)- (II-K) with the co-crystal former under crystallization conditions and isolating co-crystals thereby formed.
- Suitable co-crystal formers include those described in WO 2004/078163.
- the invention further provides co-crystals comprising a compound of Formula I, (I-A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K).
- any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration.
- each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration.
- Substituents at atoms with unsaturated bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
- a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof.
- Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
- Any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the
- a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-0,0'-p-toluoyl tartaric acid, mandelic acid, malic acid or camphor- 10-sulfonic acid. Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
- HPLC high pressure liquid chromatography
- FXR modulating properties e.g. as indicated in in vitro and/or in vivo tests as provided in the next sections, and are therefore indicated for therapy in treating a disorder which may be treated by modulating FXR, such as those described below.
- FXR regulates a complex pattern of response genes in the liver that have impact on diverse physiological processes. FXR represses the induction of Cyp7Al via the upregulation of mRNA encoding SHP, a further nuclear receptor that is dominant repressive over LRH-1.
- FXR parallel to the repression of bile acid synthesis via SHP, FXR induces a range of so-called ABC (for ATP-binding cassette) transporters that are responsible for the export of toxic bile acids from the hepatocyte cytosol into the canaliculi, the small bile duct ramifications where the bile originates.
- ABC for ATP-binding cassette
- hepatoprotective effect was further narrowed down to an anti-fibrotic effect that results from the repression of Tissue Inhibitors of Matrix-Metalloproteinases, TIMP-1 and 2, the induction of collagen-deposit resolving Matrix-Metalloproteinase 2 (MMP-2) in hepatic stellate cells and the subsequent reduction of alpha-collagen mRNA and Transforming growth factor beta (TGF-beta) mRNA which are both pro-fibrotic factors by FXR agonists (Fiorucci et al., Gastroenterology 2004, 127(5), 1497-1512; Fiorucci et al., Pharmacol. Exp. Ther. 2005, 314(2), 584-595).
- TGF-beta Transforming growth factor beta
- the anti-fibrotic activity of FXR is at least partially mediated by the induction of PPARy, a further nuclear receptor, with which anti-fibrotic activity is associated (Fiorucci et al., J. Pharmacol. Exp. Ther. 2005, 315(1), 58-68; Galli et al., Gastroenterology 2002, 122(7), 1924- 1940; Pineda Torra et al., Mol. Endocrinol. 2003, 17(2), 259-272). Furthermore, anti-cholestatic activity was demonstrated in bile-duct ligated animal models as well as in animal models of estrogen-induced cholestasis (Fiorucci et al., J. Pharmacol. Exp. Ther. 2005, 313(2), 604-612).
- FXR binding compounds will demonstrate substantial clinical utility in the therapeutic regimen of chronic cholestatic conditions such as Primary Biliary Cirrhosis (PBC) or Primary Sclerosing Cholangitis (PSC) (reviewed in: Rizzo et al., Curr. Drug Targets Immune Endocr. Metabol. Disord. 2005, 5(3), 289-303; Zollner, Mol. Pharm. 2006, 3(3), 231-51 , Cai et al., Expert Opin. Ther. Targets 2006, 10(3), 409-421).
- PBC Primary Biliary Cirrhosis
- PSC Primary Sclerosing Cholangitis
- Cholesterol gallstones form due to low solubility of cholesterol that is actively pumped out of the liver cell into the lumen of the canaliculi.
- the relative percentage of the three major components, bile acids, phospholipids and free cholesterol, determines the formation of mixed micelles and hence apparent solubility of free cholesterol in the bile.
- FXR polymorphisms map as quantitative trait loci as one factor contributing to gallstone disease (Wittenburg,
- FXR has also been shown to be a key regulator of serum triglycerides (Maloney et al., J. Med. Chem. 2000, 43(16), 2971-2974; Willson et al., Med. Res. Rev. 2001 , 21(6), 513- 22). Recent reports indicate that activation of FXR by synthetic agonists leads to significant reduction of serum triglycerides, mainly in the form of reduced VLDL, but also to reduced total serum cholesterol (Kast et al., Mol. Endocrinol. 2001 , 15(10), 1720-1728; Urizar et al., Science 2002, 296(5573), 1703- 1706; Lambert et al., J.
- Insulin sensitivity as well as glucose tolerance were positively impacted by FXR treatment (Stayrook et al., Endocrinology 2005, 146(3), 984-91 ; Zhang et al., Proc. Natl. Acad. Sci. USA 2006, 103(4), 1006-1011 ; Cariou et al., J. Biol. Chem. 2006, 281 , 11039- 11049; Ma et al., J. Clin. Invest. 2006, 116(4), 1102-1109; Duran- Sandoval et al., Biochimie 2005, 87(1), 93-98).
- said compounds and pharmaceutical compositions are used for the preparation of a medicament for the treatment of chronic intrahepatic and some forms of extrahepatic cholestatic conditions, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), progressive familiar cholestasis (PFIC), alcohol- induced cirrhosis and associated cholestasis, or liver fibrosis resulting from chronic cholestatic conditions or acute intraheptic cholestatic conditions such as estrogen or drug induced cholestasis.
- PBC primary biliary cirrhosis
- PSC primary sclerosing cholangitis
- PFIC progressive familiar cholestasis
- alcohol- induced cirrhosis and associated cholestasis or liver fibrosis resulting from chronic cholestatic conditions or acute intraheptic cholestatic conditions such as estrogen or drug induced cholestasis.
- compositions comprising said compounds are used in the treatment of Type II Diabetes which can be overcome by FXR-mediated upregulation of systemic insulin sensitivity and intracellular insulin signalling in liver, increased peripheral glucose uptake and
- the invention also relates to a compound of Formula I, (I- A) to (TY), ( ⁇ ), II, and (II- A)-(II-K), or to a pharmaceutical composition comprising said compound, for the treatment of gastrointestinal conditions with a reduced uptake of dietary fat and fat-soluble dietary vitamins which can be overcome by increased intestinal levels of bile acids and phospholipids.
- the compounds according to the invention are useful for beneficially altering lipid profiles, including but not limited to lowering total cholesterol levels, lowering LDL cholesterol levels, lowering VLDL cholesterol levels, raising HDL cholesterol levels, and/or lowering triglyceride levels.
- the present invention provides a method for treating FXR mediated conditions such as dyslipidemia and diseases related to dyslipidemia comprising administering a therapeutically effective amount of a compound of the present invention to a subject in need thereof.
- said compound or pharmaceutical composition is used for treating a disease selected from the group consisting of lipid and lipoprotein disorders such as hypercholesterolemia, hypertriglyceridemia, and atherosclerosis as a clinically manifest condition which can be ameliorated by FXR's beneficial effect on raising HDL cholesterol, lowering serum triglycerides, increasing conversion of liver cholesterol into bile acids and increased clearance and metabolic conversion of VLDL and other lipoproteins in the liver.
- lipid and lipoprotein disorders such as hypercholesterolemia, hypertriglyceridemia, and atherosclerosis
- said compound and pharmaceutical composition are used for the preparation of a medicament where the combined lipid lowering, anti- cholestatic and anti-fibrotic effects of FXR-targeted medicaments can be exploited for the treatment of liver steatosis and associated syndromes such as non-alcoholic steatohepatitis ("NASH”), or for the treatment of cholestatic and fibrotic effects that are associated with alcohol-induced cirrhosis, or with viral-borne forms of hepatitis.
- liver steatosis and associated syndromes such as non-alcoholic steatohepatitis (“NASH”)
- NASH non-alcoholic steatohepatitis
- cholestatic and fibrotic effects that are associated with alcohol-induced cirrhosis, or with viral-borne forms of hepatitis.
- FXR agonists might have clinical utility as anti- atherosclerotic and cardioprotective drugs.
- the downregulation of Endothelin-1 in Vascular Smooth Muscle Cells might also contribute to such beneficial therapeutic effects (He et al., Circ. Res. 2006, 98(2), 192-9).
- the invention also relates to a compound according to Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K), or a pharmaceutical composition comprising said compound, for preventive and posttraumatic treatment of cardiovascular disorders such as acute myocardial infarction, acute stroke, or thrombosis which occur as an endpoint of chronic obstructive atherosclerosis.
- cardiovascular disorders such as acute myocardial infarction, acute stroke, or thrombosis which occur as an endpoint of chronic obstructive atherosclerosis.
- cardiovascular disorders such as acute myocardial infarction, acute stroke, or thrombosis which occur as an endpoint of chronic obstructive atherosclerosis.
- VSMCs Vascular Smooth Muscle Cells
- FXR seems to be expressed in metastasizing breast cancer cells and in colon cancer (Silva, J. Lipid Res. 2006, 47(4), 724-733; De Gottardi et al., Dig. Dis. Sci. 2004, 49(6), 982-989).
- Other publications that focus primarily on FXR's effect on metabolism draw a line to intracellular signaling from FXR via the Forkhead /Wingless (FOXO) family of transcriptional modulators to the Phosphatidylinositol-trisphosphat (PI3)- Kinase / Akt signal transduction pathway (Duran- Sandoval et al., J. Biol. Chem.
- FXR may also be a potential target for the treatment of proliferative diseases, especially metastasizing cancer forms that overexpress FXR or those where the FOXO /PI3- Kinase / Akt Pathway is responsible for driving proliferation.
- the compounds according to Formula I, (I-A) to (I-Y), ( ⁇ ), II, and ( ⁇ - ⁇ )-( ⁇ - ⁇ ), or pharmaceutical composition comprising said compounds are suitable for treating non-malignant hyperproliferative disorders such as increased neointima formation after balloon vessel dilatation and stent application due to increased proliferation of vascular smooth muscle cells (VSMCs) or Bening Prostate Hyperplasia (BPH), a pre-neoplastic form of hyperproliferation, other forms of scar tissue formation and fibrotisation which can be overcome by e.g. FXR-mediated intervention into the PI-3Kinase / AKT / mTOR intracellular signalling pathway, reduction in Matrix-Metalloproteinase activity and alpha-Collagen deposition.
- non-malignant hyperproliferative disorders such as increased neointima formation after balloon vessel dilatation and stent application due to increased proliferation of vascular smooth muscle cells (VSMCs) or Bening Prostate Hyperplasia (
- said compounds and pharmaceutical compositions are used for the treatment of malignant hyperproliferative disorders such as cancer (e.g. certain forms of breast or prostate cancer) where interference with PI- 3- Kinase/AKT/mTOR signalling and / or induction of p27kip and / or induction of apoptosis will have a beneficial impact.
- cancer e.g. certain forms of breast or prostate cancer
- interference with PI- 3- Kinase/AKT/mTOR signalling and / or induction of p27kip and / or induction of apoptosis will have a beneficial impact.
- FXR seems also to be involved in the control of antibacterial defense in the intestine (lnagaki et al., Proc. Natl. Acad. Sci. U S A. 2006, 103(10), 3920- 3905) although an exact mechanism is not provided. From these published data, however, one can conclude that treatment with FXR agonists might have a beneficial impact in the therapy of Inflammatory Bowel Disorders (IBD), in particular those forms where the upper (ileal) part of the intestine is affected (e.g. ileal Crohn's disease) because this seems to be the site of action of FXR's control on bacterial growth. In IBD, the desensitization of the adaptive immune response is somehow impaired in the intestinal immune system.
- IBD Inflammatory Bowel Disorders
- the invention also relates to a compound according to formula (I) or a pharmaceutical composition comprising said compound for treating a disease related to Inflammatory Bowel Diseases such as Crohn's disease or Colitis ulcerosa.
- FXR- mediated restoration of intestinal barrier function and reduction in non-commensal bacterial load is believed to be helpful in reducing the exposure of bacterial antigens to the intestinal immune system and can therefore reduce inflammatory responses.
- the invention further relates to a compound or pharmaceutical composition for the treatment of obesity and associated disorders such as metabolic syndrome (combined conditions of dyslipidemias, diabetes and abnormally high body-mass index) which can be overcome by FXR-mediated lowering of serum triglycerides, blood glucose and increased insulin sensitivity and FXR-mediated weight loss.
- metabolic syndrome combined conditions of dyslipidemias, diabetes and abnormally high body-mass index
- said compound or pharmaceutical composition is for treating persistent infections by intracellular bacteria or parasitic protozoae such as Mycobacterium spec. (Treatment of Tuberculosis or Lepra), Listeria monocytogenes (Treatment of Listeriosis), Leishmania spec. (Leishmaniosis), Trypanosoma spec. (Chagas Disease; Trypanosomiasis; Sleeping Sickness).
- intracellular bacteria or parasitic protozoae such as Mycobacterium spec. (Treatment of Tuberculosis or Lepra), Listeria monocytogenes (Treatment of Listeriosis), Leishmania spec. (Leishmaniosis), Trypanosoma spec. (Chagas Disease; Trypanosomiasis; Sleeping Sickness).
- the compounds or pharmaceutical composition of the present invention are useful in the preparation of a medicament for treating clinical
- Type I and Type II Diabetes examples include Diabetic Nephropathy, Diabetic Retinopathy, Diabetic Neuropathies, Peripheral Arterial Occlusive Disease (PAOD). Other clinical complications of Diabetes are also encompassed by the present invention.
- conditions and diseases which result from chronic fatty and fibrotic degeneration of organs due to enforced lipid and specifically triglyceride accumulation and subsequent activation of profibrotic pathways may also be treated by applying the compounds or pharmaceutical composition of the present invention.
- Such conditions and diseases encompass Non- Alcoholic Steatohepatitis (NASH) and chronic cholestatic conditions in the liver,
- Glomerulosclerosis and Diabetic Nephropathy in the kidney Macula Degeneration and Diabetic Retinopathy in the eye and Neurodegenerative diseases such as Alzheimer's Disease in the brain or Diabetic Neuropathies in the peripheral nervous system.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier.
- the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration, and rectal administration, etc.
- the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions).
- compositions can be subjected to conventional pharmaceutical operations such as sterilization and/or can contain conventional inert diluents, lubricating agents, or buffering agents, as well as adjuvants, such as preservatives, stabilizers, wetting agents, emulsifers and buffers, etc.
- the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with
- diluents e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine
- lubricants e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol
- binders e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired
- disintegrants e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or
- Tablets may be either film coated or enteric coated according to methods known in the art.
- compositions for oral administration include an effective amount of a compound of the invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
- compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
- Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or an oil medium for example, peanut oil, liquid paraffin or olive oil.
- compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions.
- Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- Said compositions are prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
- compositions for transdermal application include an effective amount of a compound of the invention with a suitable carrier.
- Carriers suitable for transdermal delivery include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host.
- transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
- compositions for topical application include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, e.g., for delivery by aerosol or the like.
- topical delivery systems will in particular be appropriate for dermal application, e.g., for the treatment of skin cancer, e.g., for prophylactic use in sun creams, lotions, sprays and the like. They are thus particularly suited for use in topical, including cosmetic, formulations well-known in the art.
- Such may contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
- a topical application may also pertain to an inhalation or to an intranasal application. They may be conveniently delivered in the form of a dry powder (either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids) from a dry powder inhaler or an aerosol spray presentation from a pressurised container, pump, spray, atomizer or nebuliser, with or without the use of a suitable propellant.
- a dry powder either alone, as a mixture, for example a dry blend with lactose, or a mixed component particle, for example with phospholipids
- Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants.
- the active compound may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be desirable.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.
- Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body.
- dosage forms can be made by dissolving or dispersing the compound in the proper medium.
- Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the active compound in a polymer matrix or gel.
- Ophthalmic formulations are also contemplated as being within the scope of this invention.
- the present invention further provides anhydrous pharmaceutical compositions and dosage forms comprising the compounds of the present invention as active ingredients, since water may facilitate the degradation of certain compounds.
- Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions.
- An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions are packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose containers (e. g., vials), blister packs, and strip packs.
- compositions and dosage forms that comprise one or more agents that reduce the rate by which the compound of the present invention as an active ingredient will decompose.
- agents which are referred to herein as “stabilizers,” include, but are not limited to, antioxidants such as ascorbic acid, pH buffers, or salt buffers, etc.
- the pharmaceutical composition or combination of the present invention can be in unit dosage of about 1-1000 mg of active ingredient(s) for a subject of about 50-70 kg, or about 1-500 mg or about 1-250 mg or about 1-150 mg or about 0.5-100 mg, or about 1-50 mg of active ingredients.
- the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated. A physician, clinician or veterinarian of ordinary skill can readily determine the effective amount of each of the active ingredients necessary to prevent, treat or inhibit the progress of the disorder or disease.
- the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
- the compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.
- the dosage in vitro may range between about 10-3 molar and 10-9 molar concentrations.
- a therapeutically effective amount in vivo may range depending on the route of administration, between about 0.1-500 mg/kg, or between about 1-100 mg/kg.
- the compound of the present invention may be administered either simultaneously with, or before or after, one or more other therapeutic agent.
- the compound of the present invention may be administered separately, by the same or different route of administration, or together in the same pharmaceutical composition as the other agents.
- the invention provides a product comprising a compound of Formula I, (TA) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
- a product comprising a compound of Formula I, (TA) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K) and at least one other therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy.
- the therapy is the treatment of a disease or condition mediated by FXR.
- Products provided as a combined preparation include a composition comprising a compound of Formula I, (TA) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K), and the other therapeutic agent(s) together in the same pharmaceutical composition, or the compound of Formula I, (TA) to (I-Y), ( ⁇ ), II, and (I A)- (II-K) and the other therapeutic agent(s) in separate form, e.g. in the form of a kit.
- the invention provides a pharmaceutical composition comprising a compound of Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K), and another therapeutic agent(s). It is contemplated that the invention provides a pharmaceutical composition comprising a compound of Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K) in combination with a naturally occurring non- toxic bile acid, such as ursodeoxycholic acid, as an aid in preventing possible depletion of fat-soluble vitamins secondary to treatment with an FXR agonist.
- a naturally occurring non- toxic bile acid such as ursodeoxycholic acid
- the compounds of the invention may be administered concurrently with the naturally occurring non-toxic bile acid, either as separate entities or as a single formulation comprising a compound of Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K) and naturally occurring bile acid.
- the pharmaceutical composition may comprise a pharmaceutically acceptable excipient, as described above.
- the invention provides a kit comprising two or more separate pharmaceutical compositions, at least one of which contains a compound of Formula I, (I- A) to (I-Y), ( ⁇ ), II, and (II-A)-(II-K).
- the kit comprises means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
- An example of such a kit is a blister pack, as typically used for the packaging of tablets, capsules and the like.
- the kit of the invention may be used for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
- the kit of the invention typically comprises directions for administration.
- the compound of the invention and the other therapeutic agent may be manufactured and/or formulated by the same or different manufacturers. Moreover, the compound of the invention and the other therapeutic may be brought together into a combination therapy: (i) prior to release of the combination product to physicians (e.g. in the case of a kit comprising the compound of the invention and the other therapeutic agent); (ii) by the physician themselves (or under the guidance of the physician) shortly before administration; (iii) in the patient themselves, e.g. during sequential
- the invention provides the use of a compound of Formula I, (I- A) to (I- Y), ( ⁇ ), II, and (II-A)-(II-K) for treating a disease or condition mediated by FXR, wherein the medicament is prepared for administration with another therapeutic agent.
- the invention also provides the use of another therapeutic agent for treating a disease or condition mediated by FXR, wherein the medicament is administered with a compound of Formula I, (I- A) to (TY), ( ⁇ ), II, and (II-A)-(II-K).
- the invention also provides a compound of Formula I, (I- A) to (TY), (T), II, and (II- A)-(II-K) for use in a method of treating a disease or condition mediated by FXR, wherein the compound of Formula I, (I- A) to (TY), (T), II, and (II-A)-(II-K) is prepared for administration with another therapeutic agent.
- the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by FXR, wherein the other therapeutic agent is prepared for administration with a compound of Formula I, (I- A) to (TY), (T), II, and (II-A)-(II-K).
- the invention also provides a compound of Formula I, (I- A) to (TY), (T), II, and (II-A)-(II-K) for use in a method of treating a disease or condition mediated by FXR, wherein the compound of Formula I, (I- A) to (TY), (T), II, and (II-A)-(II-K) is administered with another therapeutic agent.
- the invention also provides another therapeutic agent for use in a method of treating a disease or condition mediated by FXR, wherein the other therapeutic agent is administered with a compound of Formula I, (I- A) to (TY), (T), II, and (II-A)-(II-K).
- the invention also provides the use of a Formula I, (I- A) to (TY), (T), II, and (ITA)- (II- K) for treating a disease or condition mediated by FXR, wherein the patient has previously (e.g. within 24 hours) been treated with another therapeutic agent.
- the invention also provides the use of another therapeutic agent for treating a disease or condition mediated by FXR, wherein the patient has previously (e.g. within 24 hours) been treated with a compound of Formula I, (I-A) to (I-Y), (T), II, and (II-A)-(II-K).
- the other therapeutic agent is useful in the treatment of dyslipidemia, cholestasis, estrogen-induced cholestasis, drug-induced cholestasis, primary biliary cirrhosis (PBC), primary sclerosing cholangistis (PSC), progressive familiar cholestatis (PFIC), alcohol-induced cirrhosis, cystic fibrosis, cholelithiasis, liver fibrosis, atherosclerosis or diabetes, particularly type II diabetes.
- the compounds of Formula I, (I-A) to (I-Y), and (II-A)-(II-K) can be prepared according to any one of Schemes I, II and III, provided infra.
- the present invention also provides a process for the production of a compound of Formula I, comprising reacting a compound of Formula III:
- R ⁇ IT and Z are as defined in Formula I;
- R 3 is -X-CO 2 R 4 wherein X is a bond or methylene;
- R 4 is Ci-6 alkyl; and R 7 is H or a protecting group;
- Each reaction step can be carried out in a manner known to those skilled in the art.
- a reaction can be carried in the presence of a suitable solvent or diluent or of mixture thereof.
- a reaction can also be carried, if needed, in the presence of an acid or a base, with cooling or heating, for example in a temperature range from approximately -30 °C to approximately 150 °C.
- a reaction is carried in a temperature range from approximately 0 °C to 100 °C, and more particularly, in a temperature range from room temperature to approximately 80 °C, in an open or closed reaction vessel and/or in the atmosphere of an inert gas, for example nitrogen.
- the compounds of Formula I, (I- A) to (TY), and (II-A)-(II-K) can be prepared following the procedures in Scheme 1 :
- the compounds of Formula I, (I- A) to (I-Y), and (II-A)-(II- K) can be prepared following the procedures in Scheme 2:
- the invention also relates to those forms of the process in which a compound obtainable as an intermediate at any stage of the process is used as starting material and the remaining process steps are carried out, or in which a starting material is formed under the reaction conditions or is used in the form of a derivative, for example in a protected form or in the form of a salt, or a compound obtainable by the process according to the invention is produced under the process conditions and processed further in situ.
- Compounds of the invention and intermediates can also be converted into each other according to methods generally known to those skilled in the art. Intermediates and final products can be worked up and/or purified according to standard methods, e.g. using chromatographic methods, distribution methods, (re-) crystallization, and the like.
- Carbohydrates Monosaccharides and Derivatives), Georg Thieme Verlag, Stuttgart 1974.
- a characteristic of protecting groups is that they can be removed readily (i.e. without the occurrence of undesired secondary reactions) for example by solvolysis, reduction, photolysis or alternatively under physiological conditions (e.g. by enzymatic cleavage).
- mixtures of isomers that are formed can be separated into the individual isomers, for example diastereoisomers or enantiomers, or into any desired mixtures of isomers, for example racemates or mixtures of diastereoisomers.
- Mixtures of isomers obtainable according to the invention can be separated in a manner known to those skilled in the art into the individual isomers; diastereoisomers can be separated, for example, by partitioning between polyphasic solvent mixtures, recrystallisation and/or chromatographic separation, for example over silica gel or by e.g.
- medium pressure liquid chromatography over a reversed phase column and racemates can be separated, for example, by the formation of salts with optically pure salt-forming reagents and separation of the mixture of diastereoisomers so obtainable, for example by means of fractional crystallisation, or by chromatography over optically active column materials.
- the solvents from which those solvents that are suitable for any particular reaction may be selected include those mentioned specifically or, for example, water, esters, such as lower alkyl-lower alkanoates, for example ethyl acetate, ethers, such as aliphatic ethers, for example diethyl ether, or cyclic ethers, for example tetrahydrofuran or dioxane, liquid aromatic hydrocarbons, such as benzene or toluene, alcohols, such as methanol, ethanol or 1- or 2- propanol, nitriles, such as acetonitrile, halogenated hydrocarbons, such as methylene chloride or chloroform, acid amides, such as dimethylformamide or dimethyl acetamide, bases, such as heterocyclic nitrogen bases, for example pyridine or N-methylpyrrolidin-2-one, carboxylic acid anhydrides, such as lower alkanoic acid anhydrides, for example acetic an
- the compounds of the present invention are either obtained in the free form, as a salt thereof, or as prodrug derivatives thereof.
- the compounds of the present invention may also form internal salts, e.g., zwitterionic molecules.
- the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound of the invention.
- Salts include in particular "pharmaceutical acceptable salts”.
- pharmaceutically acceptable salts refers to salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
- Salts of compounds of the present invention having at least one salt-forming group may be prepared in a manner known to those skilled in the art.
- salts of compounds of the present invention having acid groups may be formed, for example, by treating the compounds with metal compounds, such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid, with organic alkali metal or alkaline earth metal compounds, such as the corresponding hydroxides, carbonates or hydrogen carbonates, such as sodium or potassium hydroxide, carbonate or hydrogen carbonate, with corresponding calcium compounds or with ammonia or a suitable organic amine, stoichiometric amounts or only a small excess of the salt-forming agent preferably being used.
- metal compounds such as alkali metal salts of suitable organic carboxylic acids, e.g. the sodium salt of 2-ethylhexanoic acid
- organic alkali metal or alkaline earth metal compounds such as the corresponding hydroxides, carbonates or hydrogen carbonates
- Acid addition salts of compounds of the present invention are obtained in customary manner, e.g. by treating the compounds with an acid or a suitable anion exchange reagent.
- Internal salts of compounds of the present invention containing acid and basic salt-forming groups e.g. a free carboxy group and a free amino group, may be formed, e.g. by the neutralisation of salts, such as acid addition salts, to the isoelectric point, e.g. with weak bases, or by treatment with ion exchangers.
- Salts can be converted into the free compounds in accordance with methods known to those skilled in the art.
- Metal and ammonium salts can be converted, for example, by treatment with suitable acids, and acid addition salts, for example, by treatment with a suitable basic agent.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids, e.g., acetate, aspartate, benzoate, besylate, bromide/hydrobromide, bicarbonate/carbonate, bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride,
- chlortheophyllonate citrate, ethandisulfonate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulfate, malate, maleate, malonate, mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate, propionate, stearate, succinate, subsalicylate, tartrate, tosylate, trifluoroacetate and tris(hydroxymethyl)aminomethane salts.
- Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
- Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, sulfo salicylic acid, and the like.
- Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
- Inorganic bases from which salts can be derived include, for example, ammonium salts and metals from columns I to XII of the periodic table.
- the salts are derived from sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
- Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like.
- Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
- the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound, a basic or acidic moiety, by conventional chemical methods.
- such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
- a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
- Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
- use of non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
- Lists of additional suitable salts can be found, e.g., in "Remington's Pharmaceutical Sciences", 20th ed., Mack Publishing Company, Easton, Pa., (1985); and in "Handbook of Pharmaceutical Salts:
- the present invention also provides pro-drugs of the compounds of the present invention that converts in vivo to the compounds of the present invention.
- a pro-drug is an active or inactive compound that is modified chemically through in vivo physiological action, such as hydrolysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a subject.
- the suitability and techniques involved in making and using pro-drugs are well known by those skilled in the art.
- Prodrugs can be conceptually divided into two non-exclusive categories, bioprecursor prodrugs and carrier prodrugs. See The Practice of Medicinal Chemistry, Ch. 31-32 (Ed. Wermuth, Academic Press, San Diego, Calif., 2001).
- bioprecursor prodrugs are compounds, which are inactive or have low activity compared to the corresponding active drug compound, that contain one or more protective groups and are converted to an active form by metabolism or solvolysis. Both the active drug form and any released metabolic products should have acceptably low toxicity.
- Carrier prodrugs are drug compounds that contain a transport moiety, e.g., that improve uptake and/or localized delivery to a site(s) of action.
- a transport moiety e.g., that improve uptake and/or localized delivery to a site(s) of action.
- the linkage between the drug moiety and the transport moiety is a covalent bond
- the prodrug is inactive or less active than the drug compound
- any released transport moiety is acceptably non-toxic.
- the transport moiety is intended to enhance uptake
- the release of the transport moiety should be rapid.
- it is desirable to utilize a moiety that provides slow release e.g., certain polymers or other moieties, such as cyclodextrins.
- Carrier prodrugs can, for example, be used to improve one or more of the following properties: increased lipophilicity, increased duration of pharmacological effects, increased site- specificity, decreased toxicity and adverse reactions, and/or improvement in drug formulation (e.g., stability, water solubility, suppression of an undesirable organoleptic or physiochemical property).
- lipophilicity can be increased by esterification of (a) hydroxyl groups with lipophilic carboxylic acids (e.g., a carboxylic acid having at least one lipophilic moiety), or (b) carboxylic acid groups with lipophilic alcohols (e.g., an alcohol having at least one lipophilic moiety, for example aliphatic alcohols).
- Exemplary prodrugs are, e.g., esters of free carboxylic acids and S-acyl derivatives of thiols and O-acyl derivatives of alcohols or phenols, wherein acyl has a meaning as defined herein.
- Suitable prodrugs are often pharmaceutically acceptable ester derivatives convertible by solvolysis under physiological conditions to the parent carboxylic acid, e.g., lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di- substituted lower alkyl esters, such as the co-(amino, mono- or di-lower alkylamino, carboxy, lower alkoxycarbonyl)-lower alkyl esters, the cc-(lower alkanoyloxy, lower alkoxycarbonyl or di-lower alkylaminocarbonyl)- lower alkyl esters, such as the pivaloyloxymethyl ester and the like conventionally used in the art.
- lower alkyl esters e.g., lower alkyl esters, cycloalkyl esters, lower alkenyl esters, benzyl esters, mono- or di- substituted lower alkyl esters, such as the co
- amines have been masked as arylcarbonyloxymethyl substituted derivatives which are cleaved by esterases in vivo releasing the free drug and formaldehyde (Bundgaard, J. Med. Chem. 2503 (1989)).
- drugs containing an acidic NH group such as imidazole, imide, indole and the like, have been masked with N-acyloxymethyl groups (Bundgaard, Design of Prodrugs, Elsevier (1985)). Hydroxy groups have been masked as esters and ethers.
- EP 039,051 (Sloan and Little) discloses Mannich-base hydroxamic acid prodrugs, their preparation and use.
- the compounds of the present invention may also be obtained in the form of hydrates, or their crystals may, for example, include the solvent used for crystallization. Different crystalline forms may be present.
- the compounds of the present invention may inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, it is intended that the invention embrace both solvated and unsolvated forms.
- solvate refers to a molecular complex of a compound of the present invention (including pharmaceutically acceptable salts thereof) with one or more solvent molecules. Such solvent molecules are those commonly used in the pharmaceutical art, which are known to be innocuous to the recipient, e.g., water, ethanol, and the like.
- hydrate refers to the complex where the solvent molecule is water.
- the compounds of the present invention, including salts, hydrates and solvates thereof may inherently or by design form polymorphs.
- Compounds of the invention in unoxidized form may be prepared from N-oxides of compounds of the invention by treating with a reducing agent (e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like) in a suitable inert organic solvent (e.g. acetonitrile, ethanol, aqueous dioxane, or the like) at 0 to 80°C.
- a reducing agent e.g., sulfur, sulfur dioxide, triphenyl phosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, or the like
- a suitable inert organic solvent e.g. acetonitrile, ethanol, aqueous dioxane, or the like
- the resulting solution was allowed to stir for an additional 1 h at room temperature.
- the resulting solution was diluted with 500 ml of H 2 0, extracted with 2x700 mL of ethyl acetate and the organic layers were combined, washed with 2x300 mL of brine, dried over anhydrous sodium sulfate and
- the resulting solution was stirred for 48 h at 30°C, after which point the solids were filtered.
- the resulting precipitate was collected by filtration to give the desired product methyl 2-amino-4-fluorobenzo[d]thiazole-6-carboxylate as a yellow solid.
- trans-2-phenylcyclopropyl)methanol (rac-I-6A).
- trans-ethyl phenylcyclopropanecarboxylic acid 3.0 g, 18.5 mmol
- lithium aluminum hydride 24 mL, of a 1 M solution in THF
- N-Hydroxy-4,4-dimethylcyclohexanecarbimidoyl chloride (I-9D) was prepared by reaction of 4,4-dimethylcyclohexanecarbaldehyde oxime and N-chloro succinimide following the same protocol as described for I-6B. MS m/z 190.1 (M + 1).
- Ethyl bicyclor3.1.01hexane-6-carboxylate (I-10A).
- a solution of cyclopentene (5.0 g, 0.073 mol) and Rh 2 (OAc) 2 (23.8 mg, 0.073 mmol) in dichloromethane (23 mL) was treated with the dropwise addition of ethyl diazoacetate (7.6 mL, 0.073 mol) in dichloromethane (23 mL) over 5 hours via syringe pump. Reaction stirred for 30 min and was then passed through a basic Alumina plug (dichloromethane as the elutant) to remove any catalyst. Reaction was
- N-hydroxyspiro[2.5]octane-4-carbimidoyl chloride (1-11 J) was prepared by reaction of spiro[2.5]octane -4-carbaldehyde oxime and N-chloro-succinimide following the same protocol as described for I-6B. MS m/z 188.0 (M + 1).
- reaction mixture was poured into IN HCl and extracted with diethyl ether (3 x 60 mL).
- the organic phase was extracted with IN KOH.
- the aqueous phase was then acidified with IN HCl and extracted with dichloromethane. Evaporation of the solvent gave the title compound as a white solid; only one diastereomer was detectable by 1H NMR.
- Bicyclo[4.1.0]heptane-3-carbaldehyde oxime (I-12D) was prepared by reaction of bicyclo[4.1.0]heptane-3-carbaldehyde and hydroxylamine following the same procol as decribed for I-6c. MS m/z 140.1 (M + 1).
- N-Hydroxybicyclo[4.1.0]heptane-3-carbimidoyl chloride (I-12E) was prepared by reaction of bicyclo[4.1.0]heptane-3-carbaldehyde oxime and N-chloro-succinimide following the same protocol as described for I-6B. MS m/z 174.0 (M + 1).
- Methyl 5-cvclopropyl-3-(o-tolyl)isoxazole-4-carboxylate(I- 15D) Methyl 3- cyclopropropyl-3-oxopropanoate (5.23 g, 36.8 mmol) and (Z)-5-cyclopropyl-N-hydroxy-3-(o- tolyl)isoxazole-4-carbimidoyl chloride (6.23 g, 36.8 mmol) were combined in anhydrous methanol (50 mL) and cooled to 0 °C under a nitrogen atmosphere.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
Abstract
Description
Claims
Priority Applications (29)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU20130082A CU24152B1 (en) | 2010-12-20 | 2011-10-30 | 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS |
DK11796872.7T DK2655370T3 (en) | 2010-12-20 | 2011-11-30 | Compositions and Methods for Modulating FXR Receptors |
SG2013043864A SG191046A1 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
PL11796872T PL2655370T3 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
LTEP11796872.7T LT2655370T (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
US13/993,138 US9150568B2 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating FXR |
AP2013006926A AP3414A (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
BR112013015452-7A BR112013015452B1 (en) | 2010-12-20 | 2011-11-30 | fxr modulating compounds, their uses, their intermediates and their preparation process, and pharmaceutical composition |
JP2013546165A JP5740483B2 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for FXR modulation |
SI201131307T SI2655370T1 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
RS20170867A RS56335B1 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
EA201390934A EA025569B1 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
NZ61323411A NZ613234A (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
KR1020137019136A KR101626046B1 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
UAA201307176A UA111178C2 (en) | 2010-12-20 | 2011-11-30 | FXR MODULATION AND MODELING METHOD |
CN201180067346.8A CN103443099B (en) | 2010-12-20 | 2011-11-30 | Regulate composition and the method for FXR |
MX2013007180A MX338845B (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr. |
ES11796872.7T ES2645728T3 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods to modulate the FXR |
EP11796872.7A EP2655370B1 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
AU2011345233A AU2011345233B2 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating FXR |
CA2819825A CA2819825C (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating farnesoid x receptors |
ZA2013/04044A ZA201304044B (en) | 2010-12-20 | 2013-06-03 | Compositions and methods for modulating fxr |
TNP2013000241A TN2013000241A1 (en) | 2011-11-01 | 2013-06-05 | Compositions and methods for modulating fxr |
IL226853A IL226853A (en) | 2010-12-20 | 2013-06-10 | 3-[(1,2-oxazol-4-yl)methoxy]-8-azabicyclo[3.2.1]octane derivatives, processes for their preparation, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for the treatment of fxr-mediated conditions |
CR20130307A CR20130307A (en) | 2010-12-20 | 2013-06-20 | COMPOSITIONS AND METHODS TO MODULATE THE FXR |
MA36062A MA34767B1 (en) | 2010-12-20 | 2013-06-28 | COMPOSITIONS AND METHODS FOR FXR MODULATION |
US14/813,397 US20150366856A1 (en) | 2010-12-20 | 2015-07-30 | Compounds and methods for modulating fxr |
HRP20171615TT HRP20171615T1 (en) | 2010-12-20 | 2017-10-24 | Compositions and methods for modulating fxr |
CY20171101146T CY1119530T1 (en) | 2010-12-20 | 2017-11-02 | TOY FXR COMPOSITIONS AND ADJUSTMENT METHODS |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061425189P | 2010-12-20 | 2010-12-20 | |
US61/425,189 | 2010-12-20 | ||
US201161554297P | 2011-11-01 | 2011-11-01 | |
US61/554,297 | 2011-11-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/993,138 A-371-Of-International US9150568B2 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating FXR |
US14/813,397 Continuation US20150366856A1 (en) | 2010-12-20 | 2015-07-30 | Compounds and methods for modulating fxr |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012087519A1 true WO2012087519A1 (en) | 2012-06-28 |
Family
ID=45349296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/062724 WO2012087519A1 (en) | 2010-12-20 | 2011-11-30 | Compositions and methods for modulating fxr |
Country Status (38)
Country | Link |
---|---|
US (2) | US9150568B2 (en) |
EP (1) | EP2655370B1 (en) |
JP (1) | JP5740483B2 (en) |
KR (1) | KR101626046B1 (en) |
CN (1) | CN103443099B (en) |
AP (1) | AP3414A (en) |
AR (1) | AR084425A1 (en) |
AU (1) | AU2011345233B2 (en) |
BR (1) | BR112013015452B1 (en) |
CA (1) | CA2819825C (en) |
CL (1) | CL2013001677A1 (en) |
CO (1) | CO6801729A2 (en) |
CR (1) | CR20130307A (en) |
CU (1) | CU24152B1 (en) |
CY (1) | CY1119530T1 (en) |
DK (1) | DK2655370T3 (en) |
EA (1) | EA025569B1 (en) |
ES (1) | ES2645728T3 (en) |
GT (1) | GT201300159A (en) |
HR (1) | HRP20171615T1 (en) |
HU (1) | HUE034150T2 (en) |
IL (1) | IL226853A (en) |
JO (1) | JO3297B1 (en) |
LT (1) | LT2655370T (en) |
MA (1) | MA34767B1 (en) |
MX (1) | MX338845B (en) |
MY (1) | MY163216A (en) |
NZ (1) | NZ613234A (en) |
PE (1) | PE20140207A1 (en) |
PL (1) | PL2655370T3 (en) |
PT (1) | PT2655370T (en) |
RS (1) | RS56335B1 (en) |
SG (1) | SG191046A1 (en) |
SI (1) | SI2655370T1 (en) |
TW (1) | TWI427078B (en) |
UY (1) | UY33815A (en) |
WO (1) | WO2012087519A1 (en) |
ZA (1) | ZA201304044B (en) |
Cited By (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103007081A (en) * | 2012-11-27 | 2013-04-03 | 鞠法红 | Traditional Chinese medicine composition for curing non-alcoholic fatty liver disease |
US20130261108A1 (en) * | 2010-12-20 | 2013-10-03 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
WO2013177224A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
CN105682656A (en) * | 2013-11-05 | 2016-06-15 | 诺华股份有限公司 | Compositions and methods for modulating farnesoid x receptors |
US9370515B2 (en) | 2013-03-07 | 2016-06-21 | Califia Bio, Inc. | Mixed lineage kinase inhibitors and method of treatments |
EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
WO2016097933A1 (en) * | 2014-12-18 | 2016-06-23 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
WO2016127924A1 (en) | 2015-02-13 | 2016-08-18 | Sunshine Lake Pharma Co., Ltd. | Tricyclic compounds and uses thereof in medicine |
WO2017145040A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Methods for using fxr agonists |
WO2017145031A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Methods for using fxr agonists |
WO2017145041A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Methods for using fxr agonists |
WO2018039384A1 (en) * | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
WO2018039386A1 (en) * | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic conditions and disorders |
WO2018051230A1 (en) * | 2016-09-14 | 2018-03-22 | Novartis Ag | Combination of fxr agonists |
WO2018081285A1 (en) * | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
WO2018085148A1 (en) * | 2016-11-04 | 2018-05-11 | Hepagene Therapeutics, Inc. | Nitrogen-containing heterocyclic compounds as fxr modulators |
WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2019007418A1 (en) | 2017-07-06 | 2019-01-10 | 山东轩竹医药科技有限公司 | Fxr receptor agonist |
US10220027B2 (en) | 2011-07-13 | 2019-03-05 | Gilead Sciences, Inc. | FXR (NR1H4) binding and activity modulating compounds |
WO2019055808A1 (en) * | 2017-09-14 | 2019-03-21 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders |
WO2019053581A1 (en) | 2017-09-12 | 2019-03-21 | Novartis Ag | Pharmaceutical composition |
CN109689050A (en) * | 2016-09-14 | 2019-04-26 | 诺华股份有限公司 | New departure of FXR agonist |
WO2019089667A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
WO2019089672A1 (en) * | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid x receptor modulators |
WO2019106550A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Fxr agonists for the treatment of liver diseases |
US10329286B2 (en) | 2016-06-13 | 2019-06-25 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
WO2019120088A1 (en) | 2017-12-22 | 2019-06-27 | 四川科伦博泰生物医药股份有限公司 | Isoxazole derivative, preparation method therefor, and use thereof |
WO2019149158A1 (en) | 2018-02-02 | 2019-08-08 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous tricyclic compounds and uses thereof in medicine |
US10421730B2 (en) | 2016-06-13 | 2019-09-24 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
US10450306B2 (en) | 2016-10-04 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
WO2019229643A1 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Combinations comprising tropifexor and cenicriviroc |
WO2020011146A1 (en) * | 2018-07-11 | 2020-01-16 | 中国医药研究开发中心有限公司 | 1,2,4-oxadiazole compounds, preparation method therefor and medicinal use thereof |
WO2020021447A1 (en) | 2018-07-25 | 2020-01-30 | Novartis Ag | Nlrp3 inflammasome inhibitors |
US10633375B2 (en) | 2016-08-31 | 2020-04-28 | Jinagsu Hengrui Medicine Co., Ltd | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
WO2020156241A1 (en) | 2019-01-31 | 2020-08-06 | 中国医药研究开发中心有限公司 | Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof |
WO2020183388A1 (en) | 2019-03-13 | 2020-09-17 | Novartis Ag | Pharmaceutical composition |
US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2020234715A1 (en) | 2019-05-17 | 2020-11-26 | Novartis Ag | Nlrp3 inflammasome inhibitors |
WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
WO2021014349A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
WO2021014350A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Combination treatment of liver diseases using fxr agonists |
WO2021044351A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
WO2021053618A1 (en) | 2019-09-19 | 2021-03-25 | Novartis Ag | Treatment comprising fxr agonists |
WO2021064575A1 (en) | 2019-09-30 | 2021-04-08 | Novartis Ag | Treatment comprising the use of fxr agonists |
WO2021127483A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
WO2021252392A1 (en) * | 2020-06-09 | 2021-12-16 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
US11225473B2 (en) | 2019-01-15 | 2022-01-18 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
WO2022053651A2 (en) | 2020-09-10 | 2022-03-17 | Precirix N.V. | Antibody fragment against fap |
WO2022068815A1 (en) * | 2020-09-30 | 2022-04-07 | 中国科学院上海药物研究所 | Fxr small-molecule agonist, and preparation method therefor and use thereof |
EP3981467A1 (en) * | 2018-08-08 | 2022-04-13 | Inorbit Therapeutics Ab | COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND 	 METHODS OF MAKING AND USING THE SAME |
WO2022152770A1 (en) | 2021-01-14 | 2022-07-21 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
WO2022229302A1 (en) | 2021-04-28 | 2022-11-03 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
EP4245365A1 (en) * | 2022-03-16 | 2023-09-20 | Cascade Pharmaceuticals, Inc. | A fxr small molecule agonist, the preparation and use thereof |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
US11833150B2 (en) | 2017-03-28 | 2023-12-05 | Gilead Sciences, Inc. | Methods of treating liver disease |
WO2024028782A1 (en) | 2022-08-03 | 2024-02-08 | Novartis Ag | Nlrp3 inflammasome inhibitors |
US11958879B2 (en) | 2015-03-31 | 2024-04-16 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU24152B1 (en) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS |
CN106146483A (en) * | 2015-04-23 | 2016-11-23 | 上海迪诺医药科技有限公司 | Heterocyclic method Buddhist nun's ester derivant X receptor modulators |
CN106946867B (en) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | FXR receptor modulators and its preparation method and application |
CN108602811B (en) * | 2016-02-01 | 2021-11-16 | 轩竹生物科技有限公司 | FXR receptor agonists |
JP2019504850A (en) * | 2016-02-08 | 2019-02-21 | レデックス ファーマ ピーエルシーRedx Pharma Plc | Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives and their use as antimicrobial compounds |
AR108711A1 (en) * | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | FXR MODULATING COMPOUNDS (NR1H4) |
TW201808283A (en) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | Nitrogen-containing tricyclic compounds and uses thereof in medicine |
CN108430998B (en) * | 2016-09-28 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | Azabicyclo derivatives, preparation method and application thereof |
CA3059869C (en) | 2017-04-12 | 2022-01-04 | Il Dong Pharmaceutical Co., Ltd. | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
WO2018190643A1 (en) * | 2017-04-12 | 2018-10-18 | Il Dong Pharmaceutical Co., Ltd. | An isoxazole derivatives as nuclear receptor agonists and used thereof |
CN109265471B (en) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | FXR receptor agonists |
CN109320517B (en) * | 2017-07-31 | 2021-08-17 | 轩竹生物科技有限公司 | FXR receptor agonists |
EP3704112B1 (en) | 2017-11-01 | 2023-09-27 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid x receptor modulators |
US11370785B2 (en) | 2017-11-01 | 2022-06-28 | Bristol-Myers Squibb Company | Multicyclic compounds as farnesoid X receptor modulators |
ES2944657T3 (en) * | 2017-11-01 | 2023-06-23 | Bristol Myers Squibb Co | Alkene compounds as modulators of the farnesoid X receptor |
CN110357875B (en) * | 2018-04-10 | 2022-06-21 | 浙江海正药业股份有限公司 | Azabicyclooctane derivative, preparation method and medical application thereof |
TWI707683B (en) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Glp-1 receptor agonists and uses thereof |
WO2020001304A1 (en) * | 2018-06-26 | 2020-01-02 | 轩竹(海南)医药科技有限公司 | Fxr receptor agonist |
TWI718644B (en) | 2018-08-31 | 2021-02-11 | 美商輝瑞股份有限公司 | Combinations for treatment of nash/nafld and related diseases |
AR118050A1 (en) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | BICYCLIC COMPOUNDS REPLACED AS MODULATORS OF THE FARNESOID X RECEIVER |
CN111825701B (en) * | 2019-04-19 | 2023-12-08 | 正大天晴药业集团股份有限公司 | Tricyclic FXR modulator compounds containing benzothiazole |
JP7398605B2 (en) * | 2019-04-19 | 2023-12-15 | シャンハイ インスティチュート オブ マテリア メディカ,チャイニーズ アカデミー オブ サイエンシーズ | FXR small molecule agonists and their preparation methods and uses |
CN111825667B (en) * | 2019-04-19 | 2023-07-25 | 中国科学院上海药物研究所 | FXR small molecule agonist and preparation method and application thereof |
CN113874019A (en) | 2019-05-20 | 2021-12-31 | 辉瑞大药厂 | Combinations comprising benzodioxoles as GLP-1R agonists for the treatment of NASH/NAFLD and related diseases |
CN114728954B (en) * | 2019-11-29 | 2023-10-17 | 广东东阳光药业股份有限公司 | Novel crystal form of Tropifexor and preparation method thereof |
WO2021104021A1 (en) * | 2019-11-29 | 2021-06-03 | 广东东阳光药业有限公司 | New crystal form of tropifexor and preparation method therefor |
EP4073028A1 (en) | 2019-12-10 | 2022-10-19 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
WO2021133948A1 (en) | 2019-12-23 | 2021-07-01 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
CN115348863A (en) | 2020-03-27 | 2022-11-15 | 辉瑞公司 | Treatment of type 2 diabetes or obesity or excess body weight with 2- [ (4- {6- [ (4-cyano-2-fluorobenzyl) oxy ] pyridin-2-yl } piperidin-1-yl) methyl ] -1- [ (2S) -oxetan-2-ylmethyl ] -1H-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
WO2021233461A1 (en) * | 2020-05-22 | 2021-11-25 | 苏州晶云药物科技股份有限公司 | Novel crystal form of benzothiazole compound and preparation method therefor |
CN113024552B (en) * | 2021-03-26 | 2022-08-05 | 厦门市博瑞来医药科技有限公司 | Synthesis and application of novel non-steroidal FXR agonist |
CN113292555B (en) * | 2021-04-28 | 2022-03-18 | 武汉纽瑞斯医药科技有限公司 | Preparation method of Tropifexor |
CA3230347A1 (en) | 2021-08-31 | 2023-03-09 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
TW202408494A (en) * | 2022-06-30 | 2024-03-01 | 南韓商日東製藥股份有限公司 | Novel crystalline form of isoxazole derivate and salt thereof and pharmaceutical composition including the same |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0039051A2 (en) | 1980-04-24 | 1981-11-04 | Merck & Co. Inc. | Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them |
JPS6351354A (en) | 1986-08-21 | 1988-03-04 | Central Glass Co Ltd | Production of cyclohexanecaboxylic acid containing trifluoromethyl group |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2007056582A1 (en) | 2005-11-09 | 2007-05-18 | Memory Pharmaceuticals Corporation | 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
WO2007063391A2 (en) | 2005-12-02 | 2007-06-07 | Pfizer Limited | Spirocyclic quinazoline derivatives as pde7 inhibitors |
WO2009012125A1 (en) * | 2007-07-16 | 2009-01-22 | Eli Lilly And Company | Compounds and methods for modulating fxr |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004048349A1 (en) | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
CN101374834B (en) * | 2006-02-03 | 2011-12-14 | 伊莱利利公司 | Compounds and methods for modulating FXR |
JP2007230909A (en) * | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | Substituted isoxazole derivative |
AU2007267692B2 (en) | 2006-05-24 | 2012-06-14 | Eli Lilly And Company | Compounds and methods for modulating FXR |
EP1894924A1 (en) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
US20110034507A1 (en) * | 2007-07-02 | 2011-02-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
JP2011500727A (en) | 2007-10-22 | 2011-01-06 | シェーリング コーポレイション | Bicyclic heterocyclic derivatives and their use as modulators of GPR119 activity |
EP2289883A1 (en) * | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
US9409918B2 (en) | 2009-10-29 | 2016-08-09 | Merck Sharp & Dohme Corp. | Bridged bicyclic piperidine derivatives and methods of use thereof |
CN103391937A (en) | 2010-12-20 | 2013-11-13 | Irm责任有限公司 | Compositions and methods for modulating farnesoid x receptors |
JP2014500318A (en) | 2010-12-20 | 2014-01-09 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Compositions and methods for modulating farnesoid X receptor |
CU24152B1 (en) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 OXAZOL-8-AZABICICLO [3,2,1] OCTANO 8 IL AS FXR MODULATORS |
-
2011
- 2011-10-30 CU CU20130082A patent/CU24152B1/en active IP Right Grant
- 2011-11-30 KR KR1020137019136A patent/KR101626046B1/en active IP Right Grant
- 2011-11-30 AP AP2013006926A patent/AP3414A/en active
- 2011-11-30 EA EA201390934A patent/EA025569B1/en not_active IP Right Cessation
- 2011-11-30 PL PL11796872T patent/PL2655370T3/en unknown
- 2011-11-30 JP JP2013546165A patent/JP5740483B2/en not_active Expired - Fee Related
- 2011-11-30 WO PCT/US2011/062724 patent/WO2012087519A1/en active Application Filing
- 2011-11-30 HU HUE11796872A patent/HUE034150T2/en unknown
- 2011-11-30 SI SI201131307T patent/SI2655370T1/en unknown
- 2011-11-30 MX MX2013007180A patent/MX338845B/en active IP Right Grant
- 2011-11-30 RS RS20170867A patent/RS56335B1/en unknown
- 2011-11-30 NZ NZ61323411A patent/NZ613234A/en not_active IP Right Cessation
- 2011-11-30 SG SG2013043864A patent/SG191046A1/en unknown
- 2011-11-30 LT LTEP11796872.7T patent/LT2655370T/en unknown
- 2011-11-30 CA CA2819825A patent/CA2819825C/en active Active
- 2011-11-30 CN CN201180067346.8A patent/CN103443099B/en not_active Expired - Fee Related
- 2011-11-30 MY MYPI2013002124A patent/MY163216A/en unknown
- 2011-11-30 US US13/993,138 patent/US9150568B2/en active Active
- 2011-11-30 AU AU2011345233A patent/AU2011345233B2/en not_active Ceased
- 2011-11-30 EP EP11796872.7A patent/EP2655370B1/en active Active
- 2011-11-30 ES ES11796872.7T patent/ES2645728T3/en active Active
- 2011-11-30 PT PT117968727T patent/PT2655370T/en unknown
- 2011-11-30 PE PE2013001456A patent/PE20140207A1/en active IP Right Grant
- 2011-11-30 DK DK11796872.7T patent/DK2655370T3/en active
- 2011-11-30 BR BR112013015452-7A patent/BR112013015452B1/en not_active IP Right Cessation
- 2011-12-18 JO JOP/2011/0386A patent/JO3297B1/en active
- 2011-12-19 UY UY33815A patent/UY33815A/en not_active Application Discontinuation
- 2011-12-20 TW TW100147534A patent/TWI427078B/en not_active IP Right Cessation
- 2011-12-20 AR ARP110104800 patent/AR084425A1/en active IP Right Grant
-
2013
- 2013-06-03 ZA ZA2013/04044A patent/ZA201304044B/en unknown
- 2013-06-10 IL IL226853A patent/IL226853A/en active IP Right Grant
- 2013-06-11 CL CL2013001677A patent/CL2013001677A1/en unknown
- 2013-06-19 GT GT201300159A patent/GT201300159A/en unknown
- 2013-06-20 CR CR20130307A patent/CR20130307A/en unknown
- 2013-06-28 MA MA36062A patent/MA34767B1/en unknown
- 2013-07-08 CO CO13160561A patent/CO6801729A2/en not_active Application Discontinuation
-
2015
- 2015-07-30 US US14/813,397 patent/US20150366856A1/en not_active Abandoned
-
2017
- 2017-10-24 HR HRP20171615TT patent/HRP20171615T1/en unknown
- 2017-11-02 CY CY20171101146T patent/CY1119530T1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0039051A2 (en) | 1980-04-24 | 1981-11-04 | Merck & Co. Inc. | Mannich-base hydroxamic acid prodrugs for the improved bioavailability of non-steroidal anti-inflammatory agents, a process for preparing and a pharmaceutical composition containing them |
JPS6351354A (en) | 1986-08-21 | 1988-03-04 | Central Glass Co Ltd | Production of cyclohexanecaboxylic acid containing trifluoromethyl group |
WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2007056582A1 (en) | 2005-11-09 | 2007-05-18 | Memory Pharmaceuticals Corporation | 1 h-indazoles, benzothiazoles, 1,2-benzoisoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof |
WO2007063391A2 (en) | 2005-12-02 | 2007-06-07 | Pfizer Limited | Spirocyclic quinazoline derivatives as pde7 inhibitors |
WO2009012125A1 (en) * | 2007-07-16 | 2009-01-22 | Eli Lilly And Company | Compounds and methods for modulating fxr |
Non-Patent Citations (66)
Title |
---|
"Dorland's illutrated Medical Dictionary", W.B. SAUNDERS PUBLISHING COMPANY |
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY |
"Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329 |
"The Peptides", vol. 3, 1981, ACADEMIC PRESS |
"The Practice of Medicinal Chemistry", 2001, ACADEMIC PRESS |
ALVAREZ ET AL., HUM. MOL. GENET., vol. 13, no. 20, 2004, pages 2451 - 60 |
BIIZ ET AL., AM. J. PHYSIOL. ENDOCRINOL. METAB., vol. 290, no. 4, 2006, pages E716 - 22 |
BISHOP-BAILEY ET AL., PROC. NAT]. ACAD. SCI. U S A, vol. 101, no. L0, 2004, pages 3668 - 3673 |
BUNDGAARD, J. MED. CHEM., 1989, pages 2503 |
BUNDGAARD: "Design of Prodrugs", 1985, ELSEVIER |
CAI ET AL., EXPERT OPIN. THER. TARGETS, vol. 10, no. 3, 2006, pages 409 - 421 |
CARIOU ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 11039 - 11049 |
CHEN ET AL., GASTROENTEROLOGY., vol. 126, no. 3, 2004, pages 756 - 64 |
CLAUDEL ET AL., ARTERIOSCLER. THROMB. VASE. BIOL., vol. 25, no. 10, 2005, pages 2020 - 2030 |
CRAWLEY, EXPERT OPINION THER. PATENTS, vol. 20, no. 8, 2010, pages 1047 - 1057 |
DE GOTTARDI ET AL., DIG. DIS. SCI., vol. 49, no. 6, 2004, pages 982 - 989 |
DURAN-SANDOVAL ET AL., BIOCHIMIE, vol. 87, no. 1, 2005, pages 93 - 98 |
DURAN-SANDOVAL ET AL., J. BIOL. CHEM., vol. 280, no. 33, 2005, pages 29971 - 29979 |
FIGGE ET AL., J. BIOL. CHEM., vol. 279, no. 4, 2004, pages 2790 - 2799 |
FIORUCCI ET AL., GASTROENTEROLOGY, vol. 127, no. 5, 2004, pages 1497 - 1512 |
FIORUCCI ET AL., J. PHARMACOL. EXP. THER., vol. 313, no. 2, 2005, pages 604 - 612 |
FIORUCCI ET AL., J. PHARMACOL. EXP. THER., vol. 315, no. 1, 2005, pages 58 - 68 |
FIORUCCI ET AL., PHARMACOL. EXP. THER., vol. 314, no. 2, 2005, pages 584 - 595 |
FORMAN ET AL., CELL, vol. 81, 1995, pages 687 - 693 |
GAIII ET AL., GASTROENTEROLOGY, vol. 122, no. 7, 2002, pages 1924 - 1940 |
H.-D. JAKUBKE; H. JESCHKEIT: "Aminosauren, Peptide, Proteine", 1982, VERLAG CHEMIE |
HANNIMAN ET AL., J. LIPID RES., vol. 46, no. 12, 2005, pages 2595 - 2604 |
HE ET AL., CIRC. RES., vol. 98, no. 2, 2006, pages 192 - 9 |
HOLT ET AL., GENES DEV., vol. 17, no. 13, 2003, pages 1581 - 1591 |
HOUBEN WEYL: "Methoden der organischen Chemie", vol. 15/1, 1974, GEORG THIEME VERLAG |
HOUBEN-WEYL: "Methods of Organic Synthesis", vol. 21, 1952, THIEME |
J. CHEM. SOC., PERKIN TRANS., vol. 2, 1984, pages 1907 - 1915 |
J. F. W. MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
JOCHEN LEHMANN: "Chemie der Kohlenhydrate: Monosaccharide und Derivate", 1974, GEORG THIEME VERLAG |
KAST ET AL., MOI. ENDOCRINOL., vol. 15, no. 10, 2001, pages 1720 - 1728 |
KITTELMANN, M. ET AL., ADV. SYNTH. CATAL., vol. 345, 2003, pages 825 - 829 |
LAMBERT ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 2563 - 2570 |
LIHONG ET AL., AMERICAN DIABETES ASSOCIATION (ADA) 66TH ANNUAL SCIENTIFIC SESSIONS, June 2006 (2006-06-01) |
LIU ET AL., J. CLIN. INVEST., vol. 112, no. 11, 2003, pages 1678 - 1687 |
LNAGAKI ET AL., PROC. NATL. ACAD. SCI. USA., vol. 103, no. 10, 2006, pages 3920 - 3905 |
MA ET AL., J. CLIN. INVEST., vol. 116, no. 4, 2006, pages 1102 - 1109 |
MAKISHIMA ET AL., SCIENCE, vol. 284, 1999, pages 1362 - 1365 |
MALONEY ET AL., J. MED. CHEM., vol. 43, no. 16, 2000, pages 2971 - 2974 |
MOSCHETTA ET AL., NATURE MEDICINE, vol. 10, no. 12, 2004, pages 1352 - 1358 |
NIESOR ET AL., CURR. PHARM. DES., vol. 7, no. 4, 2001, pages 231 - 59 |
PARKS ET AL., SCIENCE, vol. 284, 1999, pages 1365 - 1368 |
PELLICCIARI ET AL., J. MED. CHEM., vol. 45, no. 17, 2002, pages 3569 - 3572 |
PINEDA TORRA ET AL., MOL. ENDOCRINOL., vol. 17, no. 2, 2003, pages 259 - 272 |
RIZZO ET AL., CURR. DRUG TARGETS IMMUNE ENDOCR. METABOL. DISORD., vol. 5, no. 3, 2005, pages 289 - 303 |
S. DOGGRELL: "New targets in and potential treatments for cholesterol gallstone disease", CURR. OPIN. INVESTIG. DRUGS, vol. 7, no. 4, 2006, pages 344 - 348, XP008175325 |
SEOL ET AL., MOL. ENDOCRINOL., vol. 9, 1995, pages 72 - 85 |
SILVA, J. LIPID RES., vol. 47, no. 4, 2006, pages 724 - 733 |
SINAI ET AL., CELL, vol. 102, no. 6, 2000, pages 731 - 744 |
STAHL; WERMUTH: "Handbook of Pharmaceutical Salts: Properties, Selection, and Use", 2002, WILEY-VCH |
STAYROOK ET AL., ENDOCRINOLOGY, vol. 146, no. 3, 2005, pages 984 - 91 |
T. W. GREENE; P. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY |
TOMLINSON ET AL., ENDOCRINOLOGY, vol. 143, no. 5, 2002, pages 1741 - 1747 |
URIZAR ET AL., SCIENCE, vol. 296, no. 5573, 2002, pages 1703 - 1706 |
WANG ET AL., MOL. CELL, vol. 3, 1999, pages 543 - 553 |
WATANABE ET AL., J. CLIN. INVEST., vol. 113, no. 10, 2004, pages 1408 - 1418 |
WESTIN ET AL., MINI REV. MED. CHEM., vol. 5, no. 8, 2005, pages 719 - 727 |
WILLSON ET AL., MED. RES. REV., vol. 21, no. 6, 2001, pages 513 - 22 |
WITTENBURG, GASTROENTEROLOGY, vol. 125, no. 3, 2003, pages 868 - 88 1 |
ZHANG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, no. 4, 2006, pages 1006 - 1011 |
ZHANG ET AL., PROC. NATL. ACAD. SCI. USA., vol. 103, no. 4, 2006, pages 1006 - 1011 |
ZOLLNER, MOL. PHARM., vol. 3, no. 3, 2006, pages 231 - 51 |
Cited By (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130261108A1 (en) * | 2010-12-20 | 2013-10-03 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
US10485795B2 (en) | 2011-07-13 | 2019-11-26 | Gilead Sciences, Inc. | FXR (NR1H4) binding and activity modulating compounds |
US10220027B2 (en) | 2011-07-13 | 2019-03-05 | Gilead Sciences, Inc. | FXR (NR1H4) binding and activity modulating compounds |
WO2013177224A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
CN103007081A (en) * | 2012-11-27 | 2013-04-03 | 鞠法红 | Traditional Chinese medicine composition for curing non-alcoholic fatty liver disease |
US9370515B2 (en) | 2013-03-07 | 2016-06-21 | Califia Bio, Inc. | Mixed lineage kinase inhibitors and method of treatments |
CN105682656A (en) * | 2013-11-05 | 2016-06-15 | 诺华股份有限公司 | Compositions and methods for modulating farnesoid x receptors |
CN105682656B (en) * | 2013-11-05 | 2019-11-05 | 诺华股份有限公司 | Adjust the composition and method of farnesoid X receptor |
EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
WO2016097933A1 (en) * | 2014-12-18 | 2016-06-23 | Novartis Ag | Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases |
WO2016127924A1 (en) | 2015-02-13 | 2016-08-18 | Sunshine Lake Pharma Co., Ltd. | Tricyclic compounds and uses thereof in medicine |
US11958879B2 (en) | 2015-03-31 | 2024-04-16 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
AU2017223155B2 (en) * | 2016-02-22 | 2019-08-22 | Novartis Ag | Methods for using FXR agonists |
WO2017145041A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Methods for using fxr agonists |
RU2743075C2 (en) * | 2016-02-22 | 2021-02-15 | Новартис Аг | Fxr agonists application methods |
EP3842043A1 (en) * | 2016-02-22 | 2021-06-30 | Novartis AG | Methods for using fxr agonists |
EP3848031A1 (en) | 2016-02-22 | 2021-07-14 | Novartis AG | Methods for using fxr agonists |
TWI735546B (en) * | 2016-02-22 | 2021-08-11 | 瑞士商諾華公司 | Methods for using fxr agonists |
US20190083481A1 (en) * | 2016-02-22 | 2019-03-21 | Novartis Ag | Methods for using fxr agonists |
WO2017145040A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Methods for using fxr agonists |
CN108697702A (en) * | 2016-02-22 | 2018-10-23 | 诺华股份有限公司 | Use the method for FXR agonists |
US11344540B2 (en) | 2016-02-22 | 2022-05-31 | Novartis Ag | Methods for treating liver disorders using FXR agonists |
AU2017223148B2 (en) * | 2016-02-22 | 2019-07-18 | Novartis Ag | Methods for using FXR agonists |
US11229634B2 (en) | 2016-02-22 | 2022-01-25 | Novartis Ag | Methods for treating gastrointestinal disorders using FXR agonists |
RU2737324C2 (en) * | 2016-02-22 | 2020-11-27 | Новартис Аг | Methods of using agonists fxr |
US11110083B2 (en) | 2016-02-22 | 2021-09-07 | Novartis Ag | Methods for treating liver disorders using FXR agonists |
WO2017145031A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Methods for using fxr agonists |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
US10981881B2 (en) | 2016-06-13 | 2021-04-20 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
US10329286B2 (en) | 2016-06-13 | 2019-06-25 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
US10774054B2 (en) | 2016-06-13 | 2020-09-15 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
US11739065B2 (en) | 2016-06-13 | 2023-08-29 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
US11247986B2 (en) | 2016-06-13 | 2022-02-15 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
US10421730B2 (en) | 2016-06-13 | 2019-09-24 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
US11718619B2 (en) | 2016-08-23 | 2023-08-08 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
US10793568B2 (en) | 2016-08-23 | 2020-10-06 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic conditions and disorders |
US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
EP3954684A1 (en) * | 2016-08-23 | 2022-02-16 | Ardelyx, Inc. | Process for the preparation of hormone receptor modulators for treating metabolic conditions and disorders |
WO2018039386A1 (en) * | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic conditions and disorders |
WO2018039384A1 (en) * | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
US10633375B2 (en) | 2016-08-31 | 2020-04-28 | Jinagsu Hengrui Medicine Co., Ltd | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
US11084808B2 (en) | 2016-08-31 | 2021-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | Oxopicolinamide derivative, preparation method therefor and pharmaceutical use thereof |
CN109689105A (en) * | 2016-09-14 | 2019-04-26 | 诺华股份有限公司 | The combination of FXR agonist |
WO2018051230A1 (en) * | 2016-09-14 | 2018-03-22 | Novartis Ag | Combination of fxr agonists |
AU2017328999B2 (en) * | 2016-09-14 | 2019-12-19 | Novartis Ag | Combination of FXR agonists |
KR102218498B1 (en) | 2016-09-14 | 2021-02-22 | 노파르티스 아게 | Combination of FXR agonists |
CN109689050A (en) * | 2016-09-14 | 2019-04-26 | 诺华股份有限公司 | New departure of FXR agonist |
KR20190044666A (en) * | 2016-09-14 | 2019-04-30 | 노파르티스 아게 | Combinations of FXR agonists |
US10450306B2 (en) | 2016-10-04 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
US11034684B2 (en) | 2016-10-04 | 2021-06-15 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
EP3523298A4 (en) * | 2016-10-04 | 2020-06-24 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
WO2018081285A1 (en) * | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
CN109963849B (en) * | 2016-11-04 | 2023-03-28 | 和博医药有限公司 | Nitrogen-containing heterocyclic compounds as FXR modulators |
AU2017354873B2 (en) * | 2016-11-04 | 2021-10-21 | Hepagene Therapeutics (HK) Limited | Nitrogen-containing heterocyclic compounds as FXR modulators |
WO2018085148A1 (en) * | 2016-11-04 | 2018-05-11 | Hepagene Therapeutics, Inc. | Nitrogen-containing heterocyclic compounds as fxr modulators |
AU2017354873C1 (en) * | 2016-11-04 | 2023-05-18 | Hepagene Therapeutics (HK) Limited | Nitrogen-containing heterocyclic compounds as FXR modulators |
US10919903B2 (en) | 2016-11-04 | 2021-02-16 | Hepagene Therapeutics (HK) Limited | Nitrogen-containing heterocyclic compounds as FXR modulators |
CN109963849A (en) * | 2016-11-04 | 2019-07-02 | 合帕吉恩治疗公司 | Nitrogen-containing heterocycle compound as FXR regulator |
WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
US11833150B2 (en) | 2017-03-28 | 2023-12-05 | Gilead Sciences, Inc. | Methods of treating liver disease |
WO2019007418A1 (en) | 2017-07-06 | 2019-01-10 | 山东轩竹医药科技有限公司 | Fxr receptor agonist |
EP3650449A4 (en) * | 2017-07-06 | 2021-04-07 | Xuanzhu Biopharmaceutical Co., Ltd. | Fxr receptor agonist |
US11352358B2 (en) | 2017-07-06 | 2022-06-07 | Xuanzhu Biopharmaceutical Co., Ltd. | FXR agonist |
WO2019053581A1 (en) | 2017-09-12 | 2019-03-21 | Novartis Ag | Pharmaceutical composition |
US11207313B2 (en) | 2017-09-12 | 2021-12-28 | Novartis Ag | Pharmaceutical composition |
AU2018332191B2 (en) * | 2017-09-12 | 2021-05-20 | Novartis Ag | Pharmaceutical composition |
JP2020533297A (en) * | 2017-09-12 | 2020-11-19 | ノバルティス アーゲー | Pharmaceutical composition |
WO2019055808A1 (en) * | 2017-09-14 | 2019-03-21 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders |
US11753410B2 (en) | 2017-09-14 | 2023-09-12 | Ardelyx, Inc. | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders |
WO2019089667A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
WO2019089672A1 (en) * | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Spirocyclic compounds as farnesoid x receptor modulators |
WO2019106550A1 (en) | 2017-11-30 | 2019-06-06 | Novartis Ag | Fxr agonists for the treatment of liver diseases |
US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
US11667629B2 (en) | 2017-12-22 | 2023-06-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
WO2019120088A1 (en) | 2017-12-22 | 2019-06-27 | 四川科伦博泰生物医药股份有限公司 | Isoxazole derivative, preparation method therefor, and use thereof |
WO2019149158A1 (en) | 2018-02-02 | 2019-08-08 | Sunshine Lake Pharma Co., Ltd. | Nitrogenous tricyclic compounds and uses thereof in medicine |
US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2019229643A1 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Combinations comprising tropifexor and cenicriviroc |
WO2020011146A1 (en) * | 2018-07-11 | 2020-01-16 | 中国医药研究开发中心有限公司 | 1,2,4-oxadiazole compounds, preparation method therefor and medicinal use thereof |
WO2020021447A1 (en) | 2018-07-25 | 2020-01-30 | Novartis Ag | Nlrp3 inflammasome inhibitors |
EP3981467A1 (en) * | 2018-08-08 | 2022-04-13 | Inorbit Therapeutics Ab | COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND 	 METHODS OF MAKING AND USING THE SAME |
US11339153B2 (en) | 2018-08-08 | 2022-05-24 | Inorbit Therapeutics Ab | Compounds useful in modulating the farnesoid X receptor and methods of making and using the same |
US11225473B2 (en) | 2019-01-15 | 2022-01-18 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
WO2020156241A1 (en) | 2019-01-31 | 2020-08-06 | 中国医药研究开发中心有限公司 | Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof |
EP3919489A4 (en) * | 2019-01-31 | 2022-10-12 | The National Institutes of Pharmaceutical R&D Co., Ltd | Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof |
US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
WO2020183388A1 (en) | 2019-03-13 | 2020-09-17 | Novartis Ag | Pharmaceutical composition |
US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2020234715A1 (en) | 2019-05-17 | 2020-11-26 | Novartis Ag | Nlrp3 inflammasome inhibitors |
WO2021009332A1 (en) | 2019-07-18 | 2021-01-21 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
WO2021014349A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Treatment comprising fxr agonists |
WO2021014350A1 (en) | 2019-07-23 | 2021-01-28 | Novartis Ag | Combination treatment of liver diseases using fxr agonists |
WO2021044351A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Methods of treating liver disease using lta4h inhibitors |
WO2021053618A1 (en) | 2019-09-19 | 2021-03-25 | Novartis Ag | Treatment comprising fxr agonists |
WO2021064575A1 (en) | 2019-09-30 | 2021-04-08 | Novartis Ag | Treatment comprising the use of fxr agonists |
WO2021127483A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
WO2021252392A1 (en) * | 2020-06-09 | 2021-12-16 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of liver disorders |
WO2022053651A2 (en) | 2020-09-10 | 2022-03-17 | Precirix N.V. | Antibody fragment against fap |
WO2022068815A1 (en) * | 2020-09-30 | 2022-04-07 | 中国科学院上海药物研究所 | Fxr small-molecule agonist, and preparation method therefor and use thereof |
WO2022152770A1 (en) | 2021-01-14 | 2022-07-21 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
WO2022229302A1 (en) | 2021-04-28 | 2022-11-03 | Enyo Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
EP4245365A1 (en) * | 2022-03-16 | 2023-09-20 | Cascade Pharmaceuticals, Inc. | A fxr small molecule agonist, the preparation and use thereof |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
WO2024028782A1 (en) | 2022-08-03 | 2024-02-08 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2655370B1 (en) | Compositions and methods for modulating fxr | |
JP2023184759A (en) | GLP-1R modulating compounds | |
KR20220042429A (en) | RIP1 inhibitory compounds and methods of making and using the same | |
JP2014500319A (en) | Compositions and methods for modulating farnesoid X receptor | |
JP2014500318A (en) | Compositions and methods for modulating farnesoid X receptor | |
JP2016510010A (en) | Trifluoromethyl-substituted ring-fused pyrimidines and uses thereof | |
KR20160079091A (en) | Compositions and methods for modulating farnesoid x receptors | |
CA2834043A1 (en) | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors | |
WO2007116866A1 (en) | Hetero compound | |
JP7264906B2 (en) | Alkene compounds as farnesoid X receptor modulators | |
TW201811766A (en) | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | |
CA3216372A1 (en) | Carboxy-benzimidazole glp-1r modulating compounds | |
JP2021501219A (en) | Alkene spiro ring compound as a farnesoid X receptor modulator | |
WO2020249064A1 (en) | Compounds for modulating fxr |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180067346.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11796872 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2819825 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013001677 Country of ref document: CL Ref document number: 13993138 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2011796872 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011796872 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12013501256 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2013546165 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001456-2013 Country of ref document: PE Ref document number: MX/A/2013/007180 Country of ref document: MX Ref document number: CR2013-000307 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13160561 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201307176 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2011345233 Country of ref document: AU Date of ref document: 20111130 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20137019136 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201390934 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013015452 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013015452 Country of ref document: BR Kind code of ref document: A2 Effective date: 20130619 |